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Anxiety disorders are the most common group of mental disorders in Aotearoa New Zealand. 
Despite the high disease burden associated with anxiety disorders, there are currently no 
objective biomarkers that can aid their diagnosis. Goal-conflict specific rhythmicity (GCSR) 
is proposed to be the first electroencephalographic (EEG) biomarker for a neural process 
contributing to clinical anxiety. Previous studies have shown GCSR to be anxiolytic sensitive 
and increased in clinically diagnosed patients, but no one has compared GCSR between 
patients and age-matched controls. The aim of the current thesis was to investigate the 
clinical validity of GCSR within patients diagnosed with DSM-IV-TR anxiety disorder 
diagnoses. We hypothesised that clinically diagnosed patients would show stronger GCSR 
than controls; high anxiety, indexed by Spielberger’s State-Trait Anxiety Inventory – Trait 
(STAI-T) items, would be linked to increased GCSR; and no specific DSM-IV-TR anxiety 
disorder diagnosis would show stronger GCSR than other diagnoses. Goal-conflict specific 
rhythmicity of 79 participants recruited from Student Job Search (SJS), 53 untreated patients 
from the community, and 35 healthy controls from the community were recorded at F8. The 
first analysis compared GCSR between SJS participants with high, medium, and low STAI-T 
scores. Participants with high STAI-T scores produced moderately stronger GCSR than the 
other two groups; the difference was statistically significant between the high STAI-T and 
medium STAI-T groups. In the second analysis, GCSR was compared between patients with 
DSM-IV-TR anxiety disorder diagnoses and healthy controls. Patients diagnosed with DSM-
IV-TR anxiety disorder diagnoses showed stronger GCSR than the control group; however, 
no significant differences in GCSR were found between patients with different STAI-T 
scores. To investigate whether the lack of difference between the two patient groups was due 
to STAI-T not being a pure measure of anxiety, multiple regression analyses were carried out 
using the Anxiety and Depressivity scores from the Personality Inventory of DSM-IV-TR 
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(PID-5) and the Neuroticism score from the Eysenck Personality Questionnaire Revised 
(EPQ-R) to predict STAI-T scores. In line with my prediction, Neuroticism, PID-Anxiety, 
and PID-Depressivity scores were found to be significant predictors of STAI-T. In the final 
analysis, GCSR was compared between patients with different primary DSM-IV-TR anxiety 
disorder diagnosis: pure generalised anxiety disorder (GAD), social anxiety disorder (SAD), 
comorbid GAD and major depressive disorder (MDD), and a group of pooled other diagnoses 
(e.g., panic disorder, post-traumatic stress disorder). Contrary to my expectations, patients 
diagnosed with comorbid GAD and MDD had significantly higher GCSR, different from the 
other diagnosis groups. Although this thesis is not without limitations, it is among the first to 
directly compare GCSR between DSM-IV-TR anxiety disorder diagnosed patients and 
controls. These results provide evidence that GCSR is a human biomarker for a process 
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Chapter 1: Introduction 
1.1 Overview of anxiety disorders 
Mental disorders are among the leading causes of disability and death in the world (Institute 
for Health Metrics and Evaluation, 2013). In Aotearoa New Zealand, nearly one in two 
individuals experience some form of mental illness during their lifetime (Oakley-Browne, 
Wells, & Scott, 2006). Mental disorders are the third leading cause of ill-health in the country, 
accounting for approximately 12% of the total disability-adjusted life years (Ministry of 
Health, 2017). At present, over 200 different diagnoses are classified by the American 
Psychiatric Association (2013) as a mental disorder. Among these, affective disorders – 
depression, bipolar, and anxiety disorders – are reported to account for the majority of the 
disease burden caused by mental illnesses (Lépine & Briley, 2011; World Health 
Organization, 2017). 
 Anxiety disorders in particular are highly prevalent. According to a national survey 
published by Oakley-Browne et al. (2006), approximately 15% of the general population are 
diagnosed with an anxiety disorder in any given year. In the same survey, nearly one in four 
New Zealanders (24.5%) were found to experience an anxiety disorder during their lifetime. 
Critically, the overall prevalence of anxiety disorders was reported to be higher than those for 
any other affective disorder, including depression (Oakley-Browne et al., 2006).  
 Anxiety disorders are linked to significant individual and financial burdens (Baxter, 
Vos, Scott, Ferrari, & Whiteford, 2014; Greenberg et al., 1999; Mendlowicz & Stein, 2000). 
Compared to non-anxious individuals, patients diagnosed with anxiety disorders report 
having poorer physical health (Ormel et al., 1994), lower employment opportunities 
(Waghorn & Chant, 2005), and reduced quality of life (Mendlowicz & Stein, 2000; Olatunji, 
Cisler, & Tolin, 2007). Patients also frequently experience occupational and social limitations 
(e.g., reduced work productivity), which translate into significant financial costs for the 
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society (Waghorn, Chant, White, & Whiteford, 2005). No research was found on the cost of 
anxiety disorders in Aotearoa New Zealand; however, in the United States, anxiety disorders 
have been estimated to cost approximately between $40-$45 billion annually (Greenberg et 
al., 1999). In a more recent study, The Royal Australian and New Zealand College of 
Psychiatrists (2016) estimated mental disorders (e.g., schizophrenia, substance-use, and 
affective disorders) to have cost the New Zealand government approximately $17 billion in 
2014. Given the high prevalence of anxiety disorders in New Zealand, it is likely that a 
significant portion of this cost was based on anxiety disorders.  
Despite the considerable health and financial losses associated with anxiety disorders, 
many patients do not receive the correct treatment. One reason for this is that health care 
professionals often have difficulties accurately identifying anxiety disorders (Fernández et al., 
2012). Earlier studies have reported that nearly 50% of depressive and anxiety disorders are 
misdiagnosed by general practitioners (Goldberg & Huxley, 1992). Though the extent of 
misdiagnosis is unclear, it is estimated that between 30-70% of patients are not provided with 
the correct specific anxiety disorder diagnosis (Bandelow et al., 2012; Bleakley & Davies, 
2014; Farach et al., 2012). Vermani, Marcus, and Katzman (2011) conducted a cross-
sectional study investigating the detection rates of specific anxiety disorders across seven 
different primary care clinics. Patients in waiting rooms were assessed using the Mini 
International Neuropsychiatric Interview (MINI; a structured interview made for diagnosing 
psychiatric disorders classified in the DSM-IV and ICD-10; Lecrubier et al., 1997). The 
patients’ medical records were then examined for any previous diagnoses of anxiety disorders. 
Patients were identified as being misdiagnosed if they met the diagnostic criteria on the MINI 
but had not been diagnosed in their medical record. Vermani et al. (2011) found high rates of 
misdiagnosis; approximately 86% of patients met criterion for panic disorder, 98% for social 
anxiety disorder (SAD), and 71% for generalised anxiety disorder (GAD). Similar findings 
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were reported in a cross-sectional study by Wittchen et al. (2002), where only 34% of 
patients with GAD were correctly diagnosed by primary care physicians. While cross-
sectional studies may not fully represent the longitudinal nature of primary care (e.g., patients 
may be diagnosed in a later session), the high rates of misdiagnosis reported in these cross-
sectional studies is still problematic. Misdiagnoses lead to the prescription of ineffective 
treatments, which can increase the severity of anxiety disorders (Bystritsky, Khalsa, Cameron, 
& Schiffman, 2013).  
 
1.2 Diagnoses of anxiety disorders and their shortcomings 
Several factors have been identified as contributing to the poor recognition of anxiety 
disorders (Bystritsky, 2006). In particular, limitations with the current diagnostic systems 
have increasingly been noted to participate in this problem. At present, ‘anxiety disorders’ are 
diagnosed based on symptoms described in the Diagnostic and Statistical Manual, 5
th
 edition 
(DSM-5; APA, 2013), as well as the new International Classification of Diseases, 11
th
 edition 
(ICD-11; WHO, 2018). In both classification systems, ‘anxiety disorders’ are defined as 
conditions that feature persistent and excessive fear and anxiety with severe physiological 
symptoms (e.g., restlessness and nausea). Twelve specific lists of symptoms are currently 
identified in the DSM-5 as ‘anxiety disorders’. These include: Separation Anxiety Disorder; 
Selective Mutism; Specific Phobias; Social Anxiety Disorder (SAD); Panic Disorder (PD); 
Agoraphobia; Generalised Anxiety Disorder (GAD); Substance/Medication-Induced Anxiety 
Disorder; Anxiety Disorder due to another medical condition; and Other Specified, or 
Unspecified, Anxiety Disorder.  
The diagnoses listed in the DSM-5 (APA, 2013) and ICD-11 (WHO, 2018) have 
limited validity because they are based on symptoms rather than biological markers. For 
example, to meet diagnostic criterion for GAD, a patient must present with at least three of 
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the six symptoms listed in the DSM-5: fatigue, issues with concentration, irritability, muscle 
tension, and sleep disturbances (APA, 2013). While symptoms often indicate the presence of 
an underlying disorder, they do not accurately predict the cause. Insel et al. (2010) argued 
that the current approach to diagnosing mental disorders is akin to identifying a medical 
illness based on signs such as ‘hypertension’ or ‘fever’. A fever can be caused by a range of 
different conditions (e.g., pneumonia or chickenpox; Centre for Disease Control, 2017; 
Meduri et al., 1994), but treatments for fevers are only effective if they address the 
underlying cause of the symptom; for example, antibiotics are effective for fevers associated 
with bacterial types of pneumonia, but not for fevers that are caused by viruses, like 
chickenpox or SARS-CoV-2 (Niederman et al., 2001). Similarly, symptoms of GAD can 
arise from different neural pathologies as supported by the fact that 30% of patients 
diagnosed with GAD are unresponsive to first-line treatments, such as selective serotonin 
reuptake inhibitors (Baldwin, 2008; Ballenger, 1999). Given the low response rate of first-
line treatments, more accurate and objective methods are needed in psychiatry to improve 
patient prognosis.  
 Another significant limitation with the DSM-5 (APA, 2013) and ICD-11 (WHO, 
2018) is that they are not designed for identifying comorbid disorders (Watson, O'Hara, & 
Stuart, 2008). Current diagnostic systems are designed to only assign one disorder per 
patient; for example, patients with GAD often show symptoms of depression, but the DSM-5 
rules out diagnosis of unipolar depression with GAD (Hirschfeld, 2001; Kroenke, Spitzer, 
Williams, Monahan, & Löwe, 2007; Mineka, and, & Clark, 1998; Moffitt, Harrington, & 
Caspi, 2007). Despite the DSM-5 (APA, 2013) being designed to diagnose one disorder, the 
rates of comorbidity are high among affective disorders. The National Comorbidity Study in 
the United States revealed that nearly 80% of individuals with lifetime GAD have a comorbid 
mood disorder (Kessler et al., 1994). A review by Goldstein-Piekarski, Williams, and 
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Humphreys (2016) reported that approximately 67% of patients with a current anxiety 
disorder show symptoms of another anxiety disorder during their lifetime. Depressive and 
anxiety disorders in particular have been reported to occur frequently together (Gorman, 
1996; Mineka et al., 1998). Patients diagnosed with comorbid anxiety and depression are 
reported to experience more severe and chronic symptoms, with a greater risk of suicide 
compared to patients diagnosed with only anxiety disorder (Zhou et al., 2017). Moffitt and 
colleagues (2007) followed 1037 males and females in Dunedin from birth for 32 years. GAD 
and MDD were diagnosed at ages 11, 13, 15, 18, 21, 26, and 32 years. During adulthood (i.e., 
ages 18, 21, 26, and 32), 12% of the cohort was found to have comorbid GAD and MDD. Of 
this 12%, over half experienced reoccurring GAD or MDD, 64% used mental health services, 
8% were in hospital, and 11% had attempted suicide. Compared to individuals diagnosed 
with only one disorder, individuals with comorbid GAD and MDD was found to have 
significantly higher rates of reoccurrence, health service use, and suicide (Moffitt et al., 2007).  
Some studies have suggested that comorbid anxiety with depression may be an 
entirely separate disorder; however, with the present diagnostic systems and their lack of 
objective markers, it is impossible to determine this (Roy-Byrne et al., 2000). Neither the 
DSM-5 (APA, 2013) nor the ICD-11 (WHO, 2018) can indicate whether anxiety and 
depression are independent disorders occurring together, if the incidence of depression is 
leading to anxiety, if the anxiety is leading to depression, or if anxiety comorbid with 
depression is a separate disorder altogether. More research is therefore needed to improve 
understanding of the neural systems underlying syndromes and to enhance the validity of 
psychiatric diagnoses.  
 Another limitation with the current diagnostic systems is their weak definitional 
boundaries between ‘fear’ and ‘anxiety’. The ICD-10 (WHO, 2004) previously categorised 
phobic disorders (e.g., agoraphobia), separately from anxiety related disorder (e.g., GAD). 
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However, in the most recent revision, the ICD-11 (WHO, 2018), merged phobic and anxiety-
related disorders to form a new class labelled ‘anxiety and fear-related disorders’. The 
frequent changes in the grouping of fear and anxiety disorders implies that little is known 
about the relationship between the two terms. This gap in knowledge is also reflected across 
the clinical and research literature (see Sylvers, Lilienfeld, & LaPrairie, 2011 for review). 
Some theorists view anxiety as chronic manifestations of fear (Rosen & Schulkin, 1998), 
whereas others see fear as unconditioned and anxiety as conditioned (Lissek et al., 2008). 
Sylvers et al. (2011) argued that the conflation of ‘fear’ and ‘anxiety’ can have negative 
implications for research and clinical progress, because researchers investigating anxiety 
could actually be measuring fear. Davidson (2002) suggested that anxiety can be evoked in 
patients by exposing them to stimuli that are known to elicit an anxiety response (e.g., a 
photo of a spider). Specific phobias though, are reported to produce avoidance behaviours, 
which are characteristic of fear rather than anxiety (explained in more detail in Sections 1.3). 
To provide more accurate diagnoses, it is important to clarify the relationship between fear 
and anxiety and to establish definitions that are more seated in biology.     
 In summary, both the DSM-5 (APA, 2013) and ICD-11 (WHO, 2018) have several 
limitations (Kupfer, 2015). As a result, the applied treatments for anxiety and other mental 
disorders have poorer rates of success than those for physical illnesses (Ormel et al., 2008). 
Cuthbert and Insel (2013) suggested that to improve treatment outcomes for patients, we must 
identify the neural systems underlying emotions, such as fear and anxiety by developing 
objective biological measures for specific disorders.  
 
1.3 Neuropsychology of fear and anxiety 
Neuropsychology is traditionally a field that aims to unify the relationship between 
complex behaviours and their underlying brain mechanisms (Berlucchi, 2009). Since studies 
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in neuropsychology assess behavioural and cognitive impairments in relation to neural 
abnormalities, it is considered to be an ideal approach to identifying the neural base of 
anxiety disorders (Hall, O'Carroll, & Frith, 2010). 
In neuropsychology, emotions such as fear and anxiety are often viewed as products 
of evolution (Barlow, Gorman, Shear, & Woods, 2000; Darwin & Prodger, 1998). While 
qualitative differences exist between species, the mechanisms underlying emotions are 
thought to be well conserved; for example, rodents, non-human primates and canines have 
been shown to have similar behavioural and physiological reactions to loss as humans 
(Sapolsky, 2016). Furthermore, the pharmacological systems that regulate negative affect are 
demonstrated to be similar in rhesus monkeys and humans (Lesch, 2011). Given that 
emotions and their neurobiological underpinnings appear to be conserved across evolution, 
McNaughton (1989) suggested that emotions can be best understood in regards to teleonomy 
(i.e., the evolutionary purpose of the adaptation; Mayr, 1974). McNaughton and Zangrossi 
(2008) viewed emotions as a cluster of independent reactions that evolved under the same 
external pressures. Though each reaction evolved separately, they all to appear to cohesively 
represent an emotion (e.g., anxiety) because they serve the same functional purpose 
(McNaughton, 1989). For example, fear is seen as a class of reactions that evolved to 
facilitate movement away from threats (Gray & McNaughton, 2000). In comparison, anxiety 
is viewed as a class of reactions that evolved to facilitate movement towards threats. Further 
discussion of Gray and McNaughton’s (2000) neuropsychological theory of fear and anxiety 
is presented in Section 1.4.  
 The brain receptors affected by drugs are also assumed to have evolved under the 
same constraints that shaped the reactions of fear and anxiety (McNaughton, 2017). Critically, 
these brain receptors are predicted to have evolved alongside the neurotransmitters and 
hormones that regulate them endogenously (Martin & Candy, 1980). Pharmacology has 
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therefore been used to distinguish fear from anxiety (Gray & McNaughton, 2000; 
McNaughton, 2017; McNaughton & Corr, 2004). Anxiolytic drugs are agents that alleviate 
the severity and duration of anxiety symptoms (Parks & Marek, 2007). As a class, anxiolytics 
are effective for some types of DSM-5 (APA, 2013) defined anxiety disorders (e.g., GAD; 
Ballenger, 1999; Graeff & Zangrossi, 2010); however, they do not have any shared effects on 
panic, phobias, obsession or depression. For example, buspirone is an anxiolytic that 
alleviates symptoms of GAD by activating serotonin 1A receptors (5HT1A), but according to 
Sheehan, Raj, Sheehan, and Soto (1990) buspirone does not have any therapeutic effects for 
panic. Conversely, panicolytics (e.g., imipramine) reduce symptoms of panic, phobias, 
depression, and anxiety (Charney et al., 1986). The different actions of anxiolytics and 
panicolytics indicate that anxiety, fear, panic, obsession, and depression are regulated by 
separate neural systems (McNaughton, 2014).  
1.4 Gray’s neuropsychological theory of fear and anxiety 
The distinct pharmacology of anxiolytic and panicolytic drugs have been used to 
construct a neuropsychological theory of fear and anxiety (Gray & McNaughton, 2000). The 
key tenet of this theory is that anxiolytics affect, and therefore define, a “Behavioural 
Inhibition System” (BIS). The BIS is theorised to regulate anxiety, which is defined in Gray 
and McNaughton’s neuropsychological theory as defensive approach. In contrast, 
panicolytics impair the Fight-Flight-Freeze System (FFFS), which is thought to be 
responsible for regulating defensive avoidance (i.e., fear). An updated version of Gray and 
McNaughton (2000)’s theory, detailing a two-dimensional (2D) model of defensive reactions 
and their disorders has since been published by McNaughton and Corr (2004). The model 
was further updated in a recent publication by Silva and McNaughton (2019; see Figure 1.1). 
 1.4.1 Fear and anxiety differ in ‘defensive direction’. The two-dimensional (2D) 
model of defensive reactions comprises two separate dimensions – defensive direction and 
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defensive distance (see Figure 1.1). As described in the previous section, fear and anxiety are 
seen as functional opposites (McNaughton & Corr, 2004). This categorical distinction is 
based on findings from Robert and Caroline Blanchard’s ethoexperimental analyses. 
Blanchard and Blanchard (1988) investigated defensive behaviours of rats in response to a cat 
(i.e., threat) within a semi-natural setting. Sudden introduction of a cat was found to elicit a 
specific class of behaviours (e.g., flight) that were reduced by drugs that alleviate panic (e.g., 
chronic administration of imipramine), but not GAD (e.g., diazepam; Blanchard, Griebel, 
Henrie, & Blanchard, 1997; Blanchard, Yudko, Rodgers, & Blanchard, 1993). Gray and 
McNaughton (2000) attributed these panicolytic-sensitive behaviours to fear. Conversely, a 
potential risk of encountering a cat – but no actual cat – was found to elicit a completely 
different set of reactions (e.g., risk assessment; Blanchard, Blanchard, Rodgers, & Weiss, 
1990b). These reactions were found to be impaired by anxiolytics but not panicolytics 
(Blanchard et al., 1997); Gray and McNaughton (2000) attributed these anxiolytic sensitive 
behaviours to anxiety. The findings from Blanchard and Blanchard (1988) and other animal 
learning studies demonstrated that fear involves responses that facilitate movement away 
from threats (i.e., defensive avoidance), while anxiety facilitates movements towards threats 
(i.e., defensive approach).  
 
ANXIETY BIOMARKER 10 
 
Figure 1.1. The two-dimensional (2D) defence system. The model was proposed by Gray 
and McNaughton (2000), revised by McNaughton and Corr (2004) and further updated in a 
publication by Silva and McNaughton (2019). On the far left is the FFFS (defensive 
avoidance/withdrawal) and in the middle is the BIS (defensive approach/conflict). On the far 
right is the BAS (approach). These parallel systems represent the categorical dimension of 
the model (i.e. defensive direction). Each system is separated into distinct hierarchical levels. 
The neural hierarchy maps onto behaviours at different defensive distances. The lower 
levels correspond to behaviours at smaller defensive distances, while higher levels regulate 
behaviours at greater defensive distance. Activity in each level is associated with specific 
sets of behaviours, as well as symptoms and syndromes. Syndromes are generated by 
hyper-reactivity in a structure, while symptoms are produced by hyper-activity. There are 
significant reciprocal connections between structures in the FFFS and BIS, which leads to 
complex symptom presentations. The name of the brain structure is in capitals, with the 
function of the structure in lower case below. Abbreviations: OFC, orbitofrontal cortex; PAG, 
periaqueductal grey. Figure taken from Silva and McNaughton (2019) and legend based on 
McNaughton and Corr (2004). 
 
1.4.2 Defensive behaviours relate to ‘defensive distance’. Defensive distance is the 
second dimension of the 2D defence system (McNaughton & Corr, 2004). This graded 
dimension is proposed to reflect the perceived distance from the threat (Blanchard & 
Blanchard, 1989; McNaughton & Corr, 2004). Defensive distance is also systematically 
related to the type of defensive behaviour that is exhibited; for example, with defensive 
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avoidance (FFFS) in rats, a short distance between the rat and the perceived threat has been 
shown to consistently elicit attack behaviours (Blanchard & Blanchard, 1988). When there is 
an intermediate distance between the rat and perceived threat, the rat either freezes or takes 
flight (depending on whether escape is possible), and at large distances the rat exhibits 
normal appetitive behaviours. Blanchard and Blanchard (1988) found that the real distance at 
which defensive behaviours occur varies between individual rats. In humans, personality 
differences have also been suggested to affect defensive distance, with braver individuals 
tending to have larger defensive distance than others (Corr & Perkins, 2006). Defensive 
distance is therefore viewed as a cognitive construct that varies between individuals 
(McNaughton & Corr, 2008). Importantly, anxiolytic drugs are proposed to alter defensive 
distance (McNaughton & Corr, 2004). With a small defensive distance, a non-drugged rat 
stays still; however, when administered anxiolytics, rats under the same condition show risk 
assessment behaviours (Blanchard, Blanchard, Tom, & Rodgers, 1990). Thus, McNaughton 
and Corr (2004) suggested that anxiolytic drugs work by increasing defensive distance rather 
than affecting a determined set of behaviours.  
As seen in Figure 1.1, defensive behaviours and their related defensive distances also 
systematically correspond to a neural hierarchy (Graeff, 1994; McNaughton & Corr, 2004). 
The smallest defensive distance (e.g., contact with predator) is thought to activate the lowest 
structure of this hierarchy (i.e., PAG). On the other hand, greater defensive distance is 
proposed to activate higher order structures, such as the orbitofrontal cortex. For example, a 
cat jumping out at touching distance is predicted to activate the dorsal areas of the PAG, 
which elicits freezing behaviour (Silva & McNaughton, 2019). A cat appearing at slightly 
greater distance is thought to activate the hypothalamus – a level above the PAG – which 
generates directed escape (Graeff, 1991). At an even greater distance, the cat is suggested to 
activate the amygdala, resulting in active avoidance. The cingulate is proposed to be linked 
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with expectation of a threat rather than an actual threat. An indication of a threat (e.g., cat 
odour) is therefore predicted to activate the cingulate, leading to simple obsessional active 
avoidance. Lastly, a threat in the future (i.e., greatest distance) is thought to activate the 
orbitofrontal cortex, resulting in complex deep obsession.  
1.4.3 Goal conflict. A critical aspect of the BIS theory is that anxiety results from 
goal-conflict (Gray & McNaughton, 2000). Goal conflict occurs when there are two 
incompatible goals activated simultaneously at similar strengths (McNaughton & Corr, 2004; 
McNaughton & Corr, 2014; McNaughton, DeYoung, & Corr, 2015). While goal-conflicts can 
occur between approach-approach and avoidance-avoidance, the most typically studied form 
of goal-conflict is between approach-avoidance (Corr & McNaughton, 2012; McNaughton & 
Corr, 2014; McNaughton et al., 2015). Approach-avoidance conflicts occur when the 
Behavioural Activation System (BAS; a system similar to the BIS and FFFS that regulates 
approach behaviours in response to appetitive stimuli; McNaughton & Corr, 2008) is 
concurrently activated with the FFFS. For examples, rodents getting cheese (i.e., appetitive 
stimuli) in an area that smells of cat (i.e., threat) or an individual with a ‘fear’ of the dark 
looking for a torch during a power outage (McNaughton & Corr, 2004). 
Activation of the BIS is proposed to result in the inhibition of pre-potent behaviours 
(Gray & McNaughton, 2000). The inhibited behaviours are replaced by responses that help 
gain more information about the environment to resolve the conflict (e.g., heightened 
vigilance, risk assessment). At the same time, the hippocampus increases the level of negative 
affect generated by the threat that is a source of conflict (Corr, 2011). As a result, the strength 
of avoidance (i.e., FFFS) is amplified, while the strength of approach (i.e., BAS) remains 
unchanged resulting in the increase of avoidance tendencies relative to approach (Corr, 2011; 
McNaughton & Corr, 2004; McNaughton & Corr, 2014). Avoidance is generally favoured 
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over approach, because evolutionarily it is more costly to be in danger than failing to get a 
reward (Langerhans, 2007).  
  
1.5 Normal, symptomatic, and syndromal output 
Activity in any level of the 2D defence system is hypothesised to generate specific 
behavioural and physiological outputs (Gray & McNaughton, 2000; McNaughton & Corr, 
2004). Depending on the level of the threat, these outputs can either be considered adaptive, 
symptomatic, or syndromal (McNaughton & Corr, 2004). For example, with an imminent 
threat (e.g., a wolf jumping onto someone), activity in the dorsal areas of the PAG would 
elicit a panic state (e.g., increased heart rate, thoughts of death). The panic state would be 
considered adaptive given the high level of threat. With symptomatic panic, the external level 
of the threat would not be high enough for the response to be adaptive (e.g., crowded place); 
however, it would still be appropriate given the level of fear or anxiety that is being 
experienced (see section 1.6.1). Alternatively, individuals with a hyper-reactive PAG would 
respond excessively to a typically non-threatening stimuli (e.g., a well-behaved dog on a 
leash). In the case with a hyper-reactive PAG, the response would be maladaptive and 
syndromal given the low level of the threat, and the individual would typically be identified 
as having a panic disorder. In addition, panic can also occur in the absence of any threat due 
to an epileptiform discharge in the PAG (Moers-Hornikx et al., 2011).  
The 2D system is highly interlinked; reciprocal connections exist both between and 
within modules of the BIS and FFFS. Although it is possible for one module to function 
independently, threats tend to activate several modules at the same time (Ledoux & Pine, 
2016). This suggestion is consistent with Fung, Qi, Hassabis, Daw, and Mobbs's (2019) fMRI 
(functional magnetic resonance imaging) study, where a distal, slow moving virtual predator 
was found to elicit BOLD activity in the ventral hippocampus, medial prefrontal cortex, 
insula and amygdala. The activation of these regions was further found to be positively linked 
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to trait anxiety scores. The broad connections between modules means that activity in any 
one structure can trigger activity in the adjacent modules; for example, activation of the 
hypothalamus in the BIS inhibits behavioural outputs from the PAG. As shown in Figure 1.1, 
the BIS medial hypothalamus is also linked with the hypothalamus of the FFFS and BAS. 
This makes sense given that co-activation of the FFFS and BAS stimulates the BIS 
(McNaughton & Corr, 2004).  
It is important to note that while both the FFFS and BIS are regulated by serotonin 
receptors, the location and density of 5HT1A receptors differ between the systems 
(McNaughton & Corr, 2008). Autoradiography studies in rodents and humans have shown 
high densities of 5HT1A receptors in different regions of the limbic system (Stiedl, Pappa, 
Konradsson-Geuken, & Ogren, 2015). In particular, a review by Hannon and Hoyer (2008) 
reported that 5HT1A receptors are especially concentrated in the hippocampus. The 
differences in the density and distribution of 5HT1A between the FFFS and BIS is predicted to 
mediate the different effects of drugs on these systems (Gray & McNaughton, 2000).  
1.6 The 2D defence model and comorbidity 
The reciprocal connections between modules in the 2D system are predicted to lead to 
comorbidities (McNaughton & Corr, 2016). According to McNaughton and Corr (2016), 
there are two different ways in which comorbidities can occur. The first way comorbidities 
can occur is when hyper-reactivity in one module (primary) causes hyper-activity in another 
structure (secondary). In this case, the hyper-reactive module is considered to be syndromal, 
while the hyper-active module is symptomatic (otherwise normal). The second way 
comorbidities can occur is when more than two modules are simultaneously hyper-reactive 
(primary); a shared risk factor (e.g., neuroticism) is predicted to contribute to this type of 
comorbidity. In this second form of comorbidity, a hyper-reactive module causes another 
module to become hyper-reactive through extensive conditioning (see section 1.6.2).  
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Figure 1.2. Example of symptomatic comorbidity arising from hyper-reactivity in the PAG. 
Hyper-reactivity (or epileptiform activity) in the PAG of the FFFS (left side) generates 
syndromal panic. Through reciprocal links in the FFFS, avoidance and arousal are increased. 
This is represented by the block arrows. The width of the arrow shows the strength of 
activation, with closer modules (e.g. medial hypothalamus) being more strongly activated 
than further modules (e.g. amygdala). The black arrows within the block arrows represent 
the available links. A panic attack, especially in neurotic individuals, can become conditioned 
with specific situations. This learning is shown by the grey dashed arrow leading from the 
PAG. This conditioning activates the hippocampus and amygdala in the BIS (right side). 
Similar to the FFFS, this activity cascades down the rest of the BIS, resulting in the 
production of anxiety. Thus, syndromal panic causes symptomatic anxiety (and fear). Given 
the high intensity of perceived threat caused by the syndromal PAG, the anxiety would be 
normal. Treatments aimed at modifying the negative perceptions of the panic attacks (e.g. 
cognitive behavioural therapy) would likely improve the anxiety, as well as some panic that is 
caused by the elevated arousal. The PAG, this, would still remain hyper-sensitive. Figure 
and legend adapted from McNaughton and Corr (2016). 
 
 
 1.6.1 Symptomatic comorbidities. Figure 1.2 illustrates an example of a hyper-
reactive module (i.e., PAG) generating hyper-activity in the BIS. Hyper-reactivity in the PAG 
elicits panic attacks (Del-Ben & Graeff, 2009; Pyke & Greenberg, 1986). Some people, 
especially those with a neurotic personality, associate the initial panic attack with certain 
environmental cues; for example, an individual experiencing a panic attack in a mall may 
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associate the panic with crowds. The association results in conditioned anxiety (e.g., 
becoming anxious of going to crowded places), which leads to increased arousal (Fell et al., 
1985). Elevated arousal causes the release of stress hormones, such as adrenaline and 
corticosterone, which trigger more panic attacks (Breggin, 1964), therefore establishing a 
vicious cycle. In the clinic, if the panic attacks persist the patient would be diagnosed with 
DSM-5 (APA, 2013) panic disorder. On the other hand, if the patient avoids situations that 
are associated with panic attacks (e.g., crowds), they would be diagnosed with agoraphobia 
with panic. McNaughton and Corr (2016) suggested that to prevent the cycle, patients should 
be taught not to try and negatively interpret the panic attacks.  
 Hyper-reactivity in the BIS can also generate hyper-activity in the PAG. A syndromal 
BIS (e.g., hyper-reactive amygdala resulting in GAD-like symptoms) may result in 
heightened arousal (Mantella et al., 2008; Van Veen et al., 2008). The elevated levels of 
adrenaline caused by hyper-reactivity in the BIS would trigger panic attacks (Del-Ben & 
Graeff, 2009; Pyke & Greenberg, 1986). The panic attacks in this case would be symptomatic 
though, as they are normal given the high levels of anxiety. The occurrence of panic attacks 
would then further cause BIS hyper-reactivity, which consequently leads to more panic 
attacks.  
1.6.2 Syndromal comorbidities. Symptomatic comorbidities can progress into 
syndromal comorbidities through extensive conditioning or ‘kindling’ (McNaughton & Corr, 
2016). In epilepsy literature, kindling refers to the phenomenon where repeated electrical 
stimulation of a neural structure results in a decreased threshold for seizure activity (Leung & 
Ma, 2017). In the FFFS and BIS, the increased levels of stress hormones released by the BIS 
alters the sensitivity of the systems involved, making them hyper-reactive (Adamec & 
McKay, 1993; Adamec & Young, 2000; Cohen, Benjamin, Kaplan, & Kotler, 2000). The 
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hyper-reactive modules then continue to reinforce each other through conditioning described 
above in Sections 1.6.1.  
 
1.7 Finding a biomarker for the Behavioural Inhibition System 
Given that symptom comorbidities can arise from various combinations of syndromal 
and symptomatic modules, superficial symptoms do not accurately reflect the pathological 
underpinnings of an anxiety disorder (McNaughton & Corr, 2016). Instead, McNaughton and 
Corr (2014) suggested that the relationship between hyper-reactive modules and their 
resulting syndrome could be used to develop a biomarker for fear and anxiety. McNaughton 
and Corr (2004) predicted that challenges aimed at eliciting activity in specific systems 
would identify different syndromes (i.e., test whether hyper-reactivity is occurring in the BIS 
or the FFFS). Individuals with a non-pathological system are predicted to generate normal 
output, whereas people with a hyper-reactive system would produce excessive output to the 
same challenge. Since the 2D neuropsychological theory is founded on the action of 
anxiolytics/panicolytics, excessive outputs from either system are predicted to be sensitive to 
the specific drugs that ameliorate behaviours related to that system (e.g., output from a hyper-
reactive BIS would likely be sensitive to anxiolytics).  
Anxiolytics, as a class, include a range of different drugs with various modes of action 
(e.g., 5HT1A agonist, GABAA agonist). Since different anxiolytic drugs work by interacting 
with specific brain receptors, they all have a diverse range of side effects. For example, 
buspirone – a 5HT1A agonist – can cause dizziness and nausea (Davidson, DuPont, Hedges, 
& Haskins, 1999; Lamberg, Kivistö, & Neuvonen, 1998; Newton, Marunycz, Alderdice, & 
Napoliello, 1986). In comparison, benzodiazepines – as GABAA agonists – are anti-
convulsants and muscle relaxants with a higher potential for abuse and dependence than 
buspirone (Bandelow et al., 2012). Despite having different side effects, all anxiolytics share 
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an effect on alleviating GAD (Davidson et al., 1999; Martin et al., 2007; Pande et al., 2003). 
Importantly, anxiolytics have no shared effects on panic, phobias, obsession or depression. 
This implies that despite the variation in receptor pathways, all anxiolytic drugs have a final 
effect on a neural function that controls anxiety (McNaughton, 2014; McNaughton, 2017). A 
neural process that is affected by all classes of anxiolytics is therefore suggested to be 
biomarker for overall BIS activity (i.e., anxiety; McNaughton, 2017; McNaughton & Corr, 
2014, 2016).  
 
Table 1.1 
Effectiveness of different drugs on treating DSM-diagnosed disorders. 
DRUG DSM DIAGNOSIS 
 GAD PHOBIA PANIC OCD DEPRESSION 
BDZ - 0 0/- 0 0 
BUS - ? 0 0 - 
PGB -  0  0 
IMI - 0 - 0 - 
CMI - ? - -- - 
MAOI ? (-) - (-) - 
SSRI - (-) - - - 
Notes. Each drug has a different therapeutic profile, but BDZ (benzodiazepines), BUS 
(buspirone and related 5HT1A agonists), and PGB (pregabalin) have a shared effect solely 
on reducing GAD (generalised anxiety disorder; dashed box). Anxiolytic drugs (grey 
background) otherwise do not have any shared effects on phobia, panic, OCD (obsessive 
compulsive disorder) or depression. Antidepressants (the white background) have clinically 
wider effects, with IMI (imipramine) reducing anxiety, panic, and depression. CMI 
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(clomipramine) have similar effects as IMI, but it also significantly reduces OCD. MAOI 
(monoamine oxidase inhibitors) have some effects on phobia, panic, OCD, and depression 
but its effects on GAD are unclear. SSRIs (selective serotonin reuptake inhibitors) reduces 
all mentioned disorders. The different pattern of drug effects indicate that there are 
different neural systems involved in their therapeutic action. This suggests that individual 
disorders, to some degree, are controlled by separate neural systems. Symbols: 0, no effect; 
-, reduction; --, significant reduction; ?, unclear. Table and legend created based on 
information from Corr and McNaughton (2012); McNaughton (2017); McNaughton and 
Zangrossi (2008) 
 
1.8 Rhythmical Slow Activity (RSA): biomarker for rodent BIS 
To date, all known classes of anxiolytics have been found to reduce the frequency of 
rhythmical slow activity (RSA) or theta activity in rodents (McNaughton & Coop, 1991). 
Rhythmical Slow Activity is a sequence of sinusoidal-looking waves found between 4-12Hz 
(theta range) in the rodent hippocampus (Gray & McNaughton, 2000). In a review, 
McNaughton, Kocsis, and Hajós (2007) reported that all drugs that alleviate symptoms of 
GAD (e.g., barbiturates, serotonin 5HT1A agonists, benzodiazepines, and ethanol) reduce the 
frequency of RSA. In contrast, drugs that do not affect GAD (e.g., antipsychotics) have not 
been found to alter RSA. The effects of anxiolytics on RSA has been reported for the last four 
decades, with no false positives or false negatives. As an example, pregabalin is a unique 
anxiolytic that affects voltage-gated calcium channels rather than 5HT or GABA receptors 
(Lauria-Horner & Pohl, 2003). Siok, Taylor, and Hajós (2009) previously tested the effects of 
pregabalin on RSA in anesthetised rats. Despite pregabalin having a unique mode of action, 
administration of the drug was found to decrease the frequency of RSA elicited by electrical 
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stimulation of the brainstem. It has been concluded that the effects of anxiolytic drugs on 
RSA are associated with their therapeutic effects (McNaughton et al., 2007).   
 A number of neural functions involve RSA, with researchers suggesting that RSA is 
important for hippocampal functions such as learning and memory (Young & McNaughton, 
2008). McNaughton, Ruan, and Woodnorth (2006) showed that blocking RSA disrupts 
spatial learning in the Morris Water Maze (see Morris, 1984). Further, the restoration of 
theta-range activity using electrical stimulation was found to improve task performance (i.e., 
restore hippocampal functions McNaughton et al., 2006). Rodents with decreased RSA 
exhibit similar behaviours to those with lesions in the hippocampus (Gray & McNaughton, 
2000). Woodnorth and McNaughton (2002) trained rats to press a lever on a fixed interval 
schedule of 60 seconds. On this hippocampal-reliant schedule, rats were only given a reward 
for a lever press 60 seconds or more after the last rewarded press. Injections of 
chlordiazepoxide (an anxiolytic) reduced RSA frequency and also increased the number of 
lever presses (i.e., released pressing behaviour that was inhibited by non-reward). Taken 
together, the findings demonstrated that RSA is important for mediating hippocampal 
functions.  
 
1.9 Goal-Conflict Specific Rhythmicity (GCSR): a potential human biomarker 
The main challenge with the standard rat test is that depth recordings require direct 
implantation of recording and stimulating electrodes into the brain (Parvizi & Kastner, 2018). 
Due to the invasive nature of this technique, depth recordings are only performed with human 
patients who require neurosurgical interventions (e.g., patients with epilepsy and tumours). 
Any other use of depth recording in humans is unethical, and so intracranial 
electroencephalography (EEG) cannot be used in the clinic to measure hippocampal activity.  
Instead, neural activity potentially related to the hippocampus can be measured 
superficially from human scalps using EEG. Several researchers have shown that 
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hippocampal theta becomes phase-locked with the prefrontal cortex during mental processing 
(Benchenane, Tiesinga, & Battaglia, 2011; Siapas, Lubenov, & Wilson, 2005). Young and 
McNaughton (2008) measured theta oscillations using EEG during four different types of 
behaviours in rats; grooming, staying still, moving around, and rearing. They found 
significant coupling of theta-like oscillations in the frontal and posterior-midline brain areas 
when the rat was either moving around or rearing. The results implied that hippocampal RSA 
becomes phase-locked with the frontal cortex during behaviours associated with risk-
assessment. It was concluded that theta-like activity in the frontal cortex, which is measurable 
with EEG from the scalp, could be used to measure BIS activity in humans.   
 Using a monetary choice task, Neo and McNaughton (2011) assessed brain activity 
from humans using scalp EEG during avoidance (loss), approach (gain), and conflict (equal 
gain and loss). The conflict between gaining money (i.e., approach) and losing money (i.e., 
avoidance) was predicted to activate the BIS. Goal-conflict specific rhythmicity (GCSR) was 
calculated by subtracting the averaged power of avoidance and approach from the conflict 
power. In the first 30 trials of the choice task, Neo and McNaughton (2011) found increased 
power during conflict at the right frontal region (i.e., F8). The findings suggested that brain 
rhythmicity recorded from the right frontal area of the scalp is related to the functioning of 
the BIS; however, the choice task had several limitations. In particular, the use of monetary 
incentive is not appropriate in the clinic. The value of money differs between individuals (e.g., 
money is likely less rewarding for rich individuals than poor students) and so, it may affect 
the strength of approach/avoidance tendencies (Mitchell & Mickel, 1999).   
Neo, Thurlow, and McNaughton (2011) found that GCSR could be elicited without 
using money in the stop-signal task (SST). The SST is a task that requires participants to 
inhibit (i.e., stop) response to stimuli (i.e., go; Verbruggen et al., 2019). Since stopping 
requires inhibition of a pre-potent response, it was predicted that the SST would elicit activity 
ANXIETY BIOMARKER 22 
in the BIS. Aron and Poldrack (2006) previously reported stopping (behavioural inhibition) in 
the SST to be contingent on activity in the right inferior frontal cortex. Using a similar 
version of the SST as Aron and Poldrack (2006), Neo and McNaughton (2011) compared the 
effects of different stop signal delays (SSDs; i.e., the interval before the stop signal is 
delivered) on EEG activity. It was assumed that the overlap between go and stop behaviours 
(intermediate delay) would elicit a more robust neural response than short or long delays. In 
line with the prediction of Neo and McNaughton (2011), GCSR was found at F8. 
Furthermore, GCSR (7-8Hz at F8) was found to be positively correlated with personality 
questionnaire scores  of neuroticism and trait anxiety (Neo & McNaughton, 2011).  
Goal-conflict specific rhythmicity was also found to be sensitive to anxiolytic drugs 
(McNaughton, Swart, Neo, Bates, & Glue, 2013). In a double-blind experiment, healthy 
participants were administered a single dose of either buspirone, triazolam, or a placebo. Both 
buspirone and triazolam were found to reduce GCSR (which occurred between 9-10Hz at F8). 
As shown in Table 1.1, buspirone and triazolam only share a common effect on reducing 
GAD (McNaughton, 2014; McNaughton & Corr, 2008). The effects of both anxiolytic drugs 
demonstrated that GCSR at F8 measured during the SST reflects a process related to the BIS. 
It is important to note that the SST does not involve any explicit threats, and so is predicted to 
not elicit panic (i.e., activity in the FFFS; McNaughton et al., 2013). In McNaughton and 
colleagues (2013) study, neither going nor stopping were found to correlate with trait anxiety 
or neuroticism scores. Furthermore, unlike the EEG pattern found at F8, stopping behaviour 
in the SST was not affected by anxiolytic drugs. The lack of correlation between personality 
measures of trait anxiety and anxiolytic effects on going and stopping behaviours implied that 
GCSR is a measure specific to activity in the BIS; unaffected by activity in the FFFS or the 
motor system (Neo et al., 2011).  
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 Shadli, Glue, McIntosh, and McNaughton (2015) revised the SST to have balanced 
numbers of trials with distinct SSDs and a clear separation between the SSD types. The 
improved version of the SST generated GCSR that was more similar in frequency (4-10Hz) 
to rodent RSA. In one experiment, Shadli et al. (2015) compared GCSR power between 
participants who were administered either buspirone, triazolam, pregabalin, or a placebo. 
Similar to the results reported in McNaughton et al. (2013), GCSR was found to be reduced 
by all three anxiolytic drugs, relative to the placebo group (Shadli et al., 2015). The GCSR 
produced in this study was also found to be positively linked with neuroticism and trait 
anxiety scores. Based on the results from Shadli et al. (2015) study, McNaughton (2017) 
proposed that GCSR measured using the modified version of the SST may be an appropriate 
biomarker for BIS activity. It was predicted that individuals with hyper-reactive BIS would 
show increased GCSR compared to individuals with adaptive BIS.  
 McIntosh (2017) recently compared GCSR between participant groups recruited from 
online advertisement on Student Job Search (SJS). Participants were split into nominally high 
and nominally low anxiety groups based on their Spielberger’s trait anxiety scores 
(Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). She found participants with high 
trait anxiety scores to generally produce stronger GCSR than participants with low scores. 
The observed differences though, were not significant. In her study, GCSR was also 
compared between a small sample of DSM-IV-TR (APA, 2000) diagnosed anxiety disorder 
patients and SJS groups with high and low trait anxiety scores. Patients diagnosed with DSM-
IV-TR (APA, 2000) anxiety disorder diagnoses showed stronger GCSR than the SJS groups. 
The preliminary analyses conducted by McIntosh (2017) indicated that GCSR may differ 
between ‘anxious’ and ‘non-anxious’ participant groups. However, her study was limited by a 
small patient sample and lack of a demographically matched control group (i.e., her control 
group was a sample of young non-clinically assessed students), and so her findings may have 
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been affected by some sampling bias. To my knowledge, no GCSR studies have investigated 
the pattern of GCSR between patients diagnosed with different DSM-IV-TR (APA, 2000) 
anxiety disorder diagnoses either. Thus, it is important to further validate GCSR within a 
larger sample of patients and to test whether GCSR is truly a biomarker for BIS anxiety.   
 
1.10 The aim and hypotheses of the present study 
In a continuation of McIntosh’s (2017) study, I investigated the clinical validity of 
GCSR across two samples of differently recruited participants; students recruited from online 
SJS and patients/healthy controls recruited from the community via advertisements for 
volunteers. In the first analysis, I compared GCSR, which was collected using Shadli and 
colleague’s (2015) version of the SST, between three groups of SJS participants with ‘high’, 
‘medium’, and ‘low’ levels of anxiety. I separated participants into these three groups using 
their trait scores from Spielberger’s State Trait Anxiety Inventory (STAI-T; Spielberger et al., 
1983). Though the STAI-T is not a pure assessment of anxiety, high scores have previously 
been linked to stronger GCSR (Neo & McNaughton, 2011; Shadli et al., 2015) and clinical 
diagnoses (Huh, Goebert, Takeshita, Lu, & Kang, 2011). Therefore, I thought that STAI-T 
scores would be a suitable index for anxiety severity. Although STAI-T is a continuous 
variable, dividing participants into groups using cut-offs is a relatively standard method of 
analysis (Gelman & Park, 2009). I split participants into groups instead of using regression 
modelling because at present, a single number cannot be derived from GCSR. Further, GCSR 
is not linear. 
In the second analysis, I compared GCSR between DSM-IV-TR (APA, 2000) anxiety 
disorder diagnosed patients and age-matched controls. To balance group size, I separated the 
patient sample into two groups – ‘patients with high STAI-T’ and ‘patients with low STAI-T’ 
– using a median split of STAI-T scores. The comparison of GCSR between DSM-IV-TR 
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(APA, 2000) anxiety disorder diagnosed patients and age-matched controls was expected to 
reduce the potential sampling biases that may have occurred in McIntosh's (2017) study.  
 While participants with high STAI-T scores have been shown to produce stronger 
GCSR, STAI-T scores are not fully reflective of GCSR (Neo & McNaughton, 2011; Shadli et 
al., 2015). To investigate whether this is because STAI-T is not a pure measure of anxiety, I 
tested the relationship between STAI-T and personality measures of neuroticism and 
depression. I performed multiple regression analyses using personality questionnaire scores 
from both the SJS and community sample. I investigated the relationship between STAI-T 
and other personality measures because the STAI-T is thought to include questions that 
assess depression, as well as anxiety (Bieling, Antony, & Swinson, 1998). 
In the final analysis, I investigated the relationship between different DSM-IV-TR 
(APA, 2000) anxiety disorder diagnoses and GCSR. Patients were separated into four 
primary diagnosis groups of generalised anxiety disorder (GAD), GAD and major depressive 
disorder (MDD), social anxiety disorder (SAD), and a pool of other anxiety disorder 
diagnoses (e.g., panic disorder, phobia).  
 I predicted that participants with high STAI-T scores would show increased GCSR 
compared to those with low STAI-T scores. I also predicted that DSM-IV-TR (APA, 2000) 
anxiety disorder diagnosed patients would produce stronger GCSR than controls. Finally, in 
line with the 2D neuropsychological theory (McNaughton & Corr, 2004; McNaughton & 
Corr, 2016), I predicted that no specific DSM-IV-TR (APA, 2000) anxiety disorder diagnosis 
would be uniquely linked to increased GCSR. The following chapters will discuss the 
methods, analyses, results and a general discussion of the findings in more detail. The next 
chapter presents the general methods for recording and analysing GCSR. Chapter 3 describes 
results from my four analyses and Chapter 4 presents a general discussion of the findings and 
their implications.   
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Chapter 2: Methods 
2.1 Participants 
Three different groups of participants were recruited for this study – students 
employed from Otago Student Job Search (SJS; an online agency where students can obtain 
casual work), first-time patients (individuals self-identifying as having anxiety recruited from 
the community), and healthy individuals (recruited from the community to demographically 
match the patient group). For analysis, these groups were separated into subgroups based on 
their Spielberger’s (1983) State Trait Anxiety Inventory trait (STAI-T) scores (see Sections 
2.1.3). The study protocol was approved by the University of Otago Ethics Committee 
(Health: H15/005), and all participants provided informed consent before taking part in the 
experiment (see Appendix A). 
2.1.1 SJS and control participants. Participants in the SJS group were recruited 
through Student Job Search and participants in the control group were recruited through 
online advertisements on Facebook. Participants in both groups reported no major illness in 
the past month, were not prescribed any psychoactive medication in the previous six months, 
and had not consumed alcohol 24 hours prior to participating in the study. None of the 
participants disclosed having any treatments for anxiety, depression or other mood disorders 
in the previous 12 months. Monetary reimbursement ($15/hour) was given to participants in 
appreciation for their time and effort.  
2.1.2 Patients. Participants in the patient group were recruited from public health 
organisations located in Dunedin and Auckland and through a variety of advertisements 
including some in the online Otago Daily Times, supermarket adverts, and Facebook. This 
group consisted of individuals who reported experiencing chronic symptoms of anxiety or 
fear, but were not receiving any pharmacological treatments for them. Medication-free 
patients were selected for this sample as anxiolytics have previously been found to alter the 
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strength of GCSR signals (McNaughton et al., 2013; Shadli et al., 2015). Participants were 
also excluded from this study if they had any history of substance abuse or other neurological 
disorders. All patients were interviewed using the Mini International Neuropsychiatric 
Interview (MINI) diagnostic examination (see Sections 2.1.1) in a separate session before 
having their electroencephalogram (EEG) measured. No patients were excluded for not 
meeting the criteria for an anxiety disorder. Similar to the control group, these participants 
were otherwise healthy. They reported no significant illness in the past month, no use of 
psychoactive medications in the previous six months, and no consumption of alcohol 24 
hours before the experiment. All patient participants received petrol vouchers ($30 worth) in 
compensation for their time and travel costs.  
2.1.3 Subgroups. I conducted three analyses of variance (ANOVA) using 3-point 
smoothed GCSR values (see section 2.7.2). In the first analysis, I separated SJS participants 
into three groups based on their STAI-T scores (high, medium and low) and conducted an 
ANOVA to test for group differences in GCSR. Although the STAI-T is a continuous 
measure, I chose to separate SJS participants into groups, because GCSR cannot be 
calculated into a single number. The relationship between GCSR and STAI-T is also not 
linear and so repeated measures ANOVA was considered to be a suitable choice of analysis. 
The numbers of participants in each group were not completely balanced as participants with 
the same STAI score were sorted into the same group. The high STAI-T group had 27 
participants (M=48.1, SD=5.6 STAI-T score); the medium STAI-T group had 27 participants 
(M=36.3 SD=1.6); and the low STAI-T group had 25 participants (M=29.6, SD=3.0). The 
second analysis involved patients and controls recruited from the community. I split patients 
into two groups based on STAI-T scores (high or low). The separation was determined by a 
median split, with a cut-off being at 55. Similar to the first analysis, ANOVA was used to 
investigate the differences between three groups: the high STAI-T patient group had 28 
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participants (Mean=60.8, SD=4.5); the low STAI-T patient group had 28 participants 
(Mean=48.8, SD=5.7); and the healthy control group had 29 participants (Mean =37.6, 
SD=9.5). In the third analysis, patients were separated into four groups based on their 
Diagnostic and Statistical Manual, 4
th
 edition text revision (DSM-IV-TR) diagnosis: (1) 
Generalised Anxiety Disorder (GAD) alone (N=15); (2) GAD with concurrent Major 
Depressive Disorder (MDD; N=14); (3) Social Anxiety Disorder (SAD; N=14); and, (4) 
Others (patients with primary diagnoses of panic, anorexia, PTSD etc.; N=10). 
 
2.2 Apparatus/Materials 
2.2.1 Mini International Neuropsychiatric Interview (MINI). As part of the 
recruitment procedure, participants in the patient group were administered the MINI (ver 
6.0.0; American Psychiatric Association, 1994). The MINI is a short structured interview 
created to assist diagnosis of common Axis-1 psychiatric disorders presented in DSM-IV and 
ICD-10 (Hergueta, Baker, & Dunbar, 1998). Despite its brevity, the MINI is reported to have 
similar levels of validity and reliability as other structured interviews used in the clinic 
(Lecrubier et al., 1997). It involves a number of concise, closed questions that are related to 
15 of the most common diagnostic categories, including: Major Depressive Episode, 
Suicidality, Manic and Hypomanic Episode, Panic Disorder, Agoraphobia, Social Phobia, 
Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Alcohol Dependence/Abuse, 
Substance Dependence/Abuse (Non-alcohol), Psychotic Disorders, Anorexia Nervosa, 
Bulimia Nervosa, Generalised Anxiety Disorder, and Anti-Social Personality Disorder. At the 
end of each module, the interviewer indicated on the MINI whether diagnostic criteria were 
met for that particular diagnosis. Interviews for this study were carried out by a psychiatrist 
or a clinical psychology trainee, trained by a psychiatrist, in a quiet, secluded room.  
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2.2.2 Stimuli Presentation and Recording. The questionnaires and stop-signal task 
(SST) were displayed on a PC computer screen, sized 360mm x 375mm, and positioned at 
eye-level approximately 120cm away from the participant’s head. Audio tones serving as a 
stop-signal for a portion of the trials were delivered through a set of headphones. During the 
SST, participants responded to the presented stimuli using the left and right buttons on a 
standard computer mouse. Right-handed participants placed their index finger on the left 
button, and their middle finger on the right button to respond to the corresponding left/right 
arrows on the screen. Left-handed participants placed their middle finger on the left mouse 
button and their index finger on the right mouse button to make left/right arrow responses. 
All tasks and questionnaires were run on purpose-built programmes coded in Visual Basic 6. 
2.2.3 Questionnaires. Responses to personality questionnaires were collected for the 
purpose of future analysis of correlations between current measures of personality and EEG 
measures, and were not all related to the measures used in this study. In particular, the current 
analyses used only STAI-T scores to differentiate participants. For this reason, only a portion 
of the questionnaire data are reported in this thesis.  
I obtained demographic data relating to gender, age, ethnicity (using the standard 
Statistics New Zealand format), and handedness from all participants before administering 
the questionnaires. Participant’s height and weight were also recorded using standard New 
Zealand metrics (height in centimetres and weight in kilograms). Participants were required 
to complete two sets of personality questionnaires via a computer-run program. Both series 
were identical to the versions used in McIntosh (2017). The first set of questionnaires were 
presented before cap fitting. It included the Trait Anxiety scale items from the STAI (State-
Trait Anxiety Inventory; Spielberger et al., 1983), the Extraversion and Neuroticism items 
from the EPQ-R (Eysenck Personality Questionnaire-Revised; Eysenck & Eysenck, 1991), 
and the BIS items from the BIS/BAS scale (Behavioural Inhibition System/Behavioural 
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Activation System; Carver & White, 1994). To gain more detail on the relationship between 
EPQ-R and GCSR for the main study, a 4-point response scale was used for the EPQ-R items 
(No-almost never; No-sometimes; Yes-often; Yes-almost always) instead of the typical 2-
point scale (No; Yes); but these were later collapsed to Yes/No for conventional scoring.  
The second set of questionnaires was delivered after the participant had finished the 
SST. This set consisted of ten scales from the PID-5 (APA, 2013) including the 
Depressiveness, Anxiousness, Emotional Liability, Perseveration, Separation Insecurity, 
Withdrawal, Anhedonia, Risk-taking, Intimacy Avoidance, and Restricted Affectivity scale 
items. Probes regarding sleep and history of depression were included within this series.  
2.2.4 EEG Recording. Waveguard caps assembled with Ag/AgCl electrodes, 
connected to 33 channels of an ASA Neurotechnology system (ANT Neuro, Enschede, The 
Netherlands) were used for recording. Participants were fitted a small (48-53cm), medium 
(53-57cm) or large (57-62cm) EEG cap depending on the circumference of their head. EEG 
signals were recorded, with CPz as recording reference and the F8 electrode of the 
International 10:20 system was used for GCSR amplitude analysis. Ocular artefacts caused 
by eye-blinks were detected via Fp1, and GND (anterior to Fz) was used as the ground 
electrode. All electrodes were later re-referenced to the common average of A1 and A2 
mastoid electrodes. Impedance at each electrode was lowered to below 20kΩ by injecting 
conductance gel (Electro Cap International, Eaton, OH, USA) using a 10ml syringe with a 
16-gauge rounded needle (Precision Glide Needle, Becton Dickinson, Franklin lakes, NJ, 
USA) between the electrodes and the participant’s scalp. Level of impedance at each 
electrode was displayed on the recording computer by the ASA program. Neural activity was 
recorded at a sampling rate of 512Hz, with band pass filters set at 1-36 Hz, and was down-
sampled to 128Hz for analysis. All EEG recordings were carried out in a certified body 
protected room equipped with the apparatus described above.  
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2.3 General Procedure 
After they provided written consent, I asked participants to complete the first set of 
questionnaires. I then measured the participant’s head circumference and marked locations 
for Fp1 and Fp2 on their foreheads with a marker in accordance to the 10:20 system. Based 
on these measurements an appropriate EEG cap was selected from the three available sizes. 
These caps were then connected to the EEG machine and fitted on the participants head; 
impedance at each electrode was lowered using the method described above. Once 
appropriate levels of impedance were achieved, participants were asked to engage in some 
jaw clenching and eye-blinking. This was done to check for any abnormalities in the signals 
and to demonstrate to the participants the noise these movements create. Any visible 
anomalies were then adjusted by moving the cord or using the syringe and needle to fine-tune 
specific electrodes.  
I then asked participants to complete a SST on the screen in front of them. 
Instructions regarding the task, equivalent to the directions given in Aron and Poldrack 
(2006) study, were given verbally by the experimenter before starting the program. 
Participants were asked to respond as fast as possible to stimuli appearing on the computer 
screen using the computer mouse. On trials where there was an auditory tone, participants 
were instructed to try and inhibit their response. The importance of responding as fast as 
possible on both go and stop trials was emphasised by the experimenter during this 
explanation. After finishing the SST, participants were asked to complete the second set of 
questionnaires. This was followed by an electrocardiography (ECG) recording. Four Ambu 
White Sensor 0425M ECG electrodes (Ambu A/S Baltorpbakken 13 DK-2750 Ballerup, 
India) were placed on both arms and legs of the participant to measure electrical activity from 
the heart. This was measured during a 10-minute relaxation period where participants 
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alternated between having their eyes open or closed every minute. EEG data continued to be 
recorded during this period to measure changes during relaxation states. ECG and EEG data 
recorded here were not relevant to the current thesis and so are not reported. After 10 minutes 
of recording, participants had their ECG electrodes and EEG cap removed by the 
experimenter. Participants were then cleaned of gel, thanked for their participation, and given 
their reimbursement before leaving the laboratory.    
 
Figure 2.1. Order of events during a trial in the Stop-Signal Task. Each trial started with a 
white fixation circle appearing in the middle of a blank screen. This circle then turned green 
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stop signal (1000Hz tone) being presented at varied intervals. Feedback on performance 
was delivered in the form of a smiley or frowny face depending on the participant’s response. 
A blank screen was inserted between each trial (jitter period). On Go trials, a response was 
followed immediately by jitter time ranging from 0.5 and 4s (average of 1s; taken from an 
exponential distribution, cut-off at 4s) as in Aron and Poldrack (2006). On Stop trials, if the 
response was successfully inhibited, the stimulus remained on the screen for 1000ms, 
followed by a jitter period; failed inhibition (i.e. response), similar to the Go trial, was followed 
immediately by jitter time. Figure provided by Neil McNaughton, adapted from Shadli et al. 
(2015). 
 
2.4 Stop Signal Task (SST) Procedure 
The stop-signal task (SST; Logan & Cowan, 1984) is used in a wide range of studies 
to assess response inhibition (Lipszyc & Schachar, 2010; Verbruggen et al., 2019). EEG 
studies using time-frequency analyses have found activity within the theta frequency range to 
be a hallmark of successful action-stopping (Yamanaka & Yamamoto, 2010). Increased theta 
power has also been observed when going and stopping are in maximal conflict (Neo & 
McNaughton, 2011). It is thought that this theta activity is associated with the function of the 
behavioural inhibition system (BIS; Corr, DeYoung, & McNaughton, 2013; Mitchell, 
McNaughton, Flanagan, & Kirk, 2008). For this reason, I used a modified version  of Aron 
and Poldrack (2006) SST in the current study. 
Figure 2.1 shows a flow diagram of the task. The computer code for the base version 
of this task was the same as Aron and Poldrack (2006) and was kindly provided by Dr Aron 
and translated from C into Visual Basic by Neil McNaughton. There were two main types of 
trials – Go and Stop. During the Go trials, a white fixation circle was presented in the middle 
of a black screen. A left (<=) or right (=>) arrow appeared inside this circle 500ms later, 
turning the fixation circle green. Participants were instructed to respond as fast as possible to 
the arrows using the corresponding buttons on the computer mouse (i.e. a right (=>) arrow 
required a right button click, left (<=) arrow a left click). The arrow and fixation circle were 
programmed to disappear after a response or following 1000ms of no response. During the 
Stop trials, a stop signal indicated by a 1000Hz tone was delivered at varying intervals (see 
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Sections 2.5). Participants were instructed to inhibit their responses on these trials by 
preventing themselves from clicking the mouse. 
The current SST had three blocks of trials, each separated by a one to two-minute rest 
break. Each block contained 132 trials, containing 99 Go trials and 33 Stop trials. Trials were 
pseudo-randomised with 1 Stop trial and 3 Go trials in each set of 4 trials. The Stop trials 
were programmed to occur in different positions during each set of 4 trials, but the pattern of 
presentation was identical for every participant.   
 Several additions were made to the original task to improve its capacity to detect 
conflict-related effects. These improvements are detailed in Shadli et al. (2015). As shown in 
Figure 2.1, feedback on performance was given to participants 500ms after each response. On 
Go trials, participants received a smiley face for a correct response, a frowny face for an 
incorrect one, and a frowny face if they did not respond within 1500ms after the arrow had 
been presented. A ‘Slow!’ feedback was given to participants if they delayed their responses 
for too long (1.5 x Go RT) to prevent participants from increasing their chances of stopping 
successfully later by strategically slowing down their Go response reaction times. On Stop 
trials, a smiley face was presented if the participant successfully inhibited their response and 
a frowny face if they made a response. Before the test blocks, participants completed a 
practice block consisting of 30 Go trials with no Stop trials. The practice block was designed 
to be a Choice Reaction Time (CRT) task similar to the version used by Carter et al. (2003). 
The purpose of the CRT was to assess participants’ Go response tendencies in order to 
estimate Go Mean Reaction Times (GoMRT). The GoMRTs were then used to calculate 
maximum Go reaction time, which was used to control delay values for the primary Stop 
trials (see Sections 2.5). 
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2.5 Stop-Signal Delay Procedure 
The interval from the start of the trial to the stop signal (the stop-signal delay; SSD) 
was varied across trials. This was managed by a computer program using a staircase tracking 
algorithm. In this task, similar to Carter et al. (2003), the short and long SSDs were 
programmed to be 20% and 80% of the mean reaction time of the previous 16 Go trials. 
Initial delay for the medium staircase was adjusted to be 45% of the previous Go reaction 
times; but the medium staircase value then changed across trials depending on the 
participant’s performance on the previous Stop trial. If the participant was successful at 
stopping, the SSD value increased by 30ms, making inhibition more difficult in the following 
Stop trial, and if they were unsuccessful the value decreased by 30ms, making inhibition 
easier in the subsequent trial. Although the staircase method for the medium SSD was based 
on Aron and Poldrack's (2006) study, the steps were programmed to be 30ms apart, as shown 
in Shadli et al., 2015, compared to the original 50ms. The medium SSD was also 
programmed so it could not move within 50ms of the other SSD staircases. It was expected 
that this procedure would track 50% correct stopping for intermediate trials and so produce 
maximum conflict between going and stopping, with a clear separation between the SSDs of 
the three staircases.  
 
2.6 Data Processing 
2.6.1 Behavioural Data. For each trial in the SST: the trial and block number, trial 
type (Go or Stop), SSD, reaction time (RT), staircase index (1-3), movement on the staircase, 
and the type of response (Left/Right or Null) were measured. Based on these data, three 
summary behavioural measures were calculated. This included: (1) the average Go reaction 
time (GoRT, ms) across all Go trials; (2) average SSD from the middle staircase; and (3) the 
Stop-Signal Reaction Time (SSRT). The SSRT was calculated in accordance to the Horse 
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Race Model described by Logan and Cowan (1984). SSRT was computed by subtracting the 
average SSD of the intermediate staircase from the median GoRT.    
2.6.2 Artefact Removal. EEG recordings often contain undesired artefacts (Reddy & 
Narava, 2013; Teplan, 2002). To remove these artefacts, data were processed through a set of 
purpose-built software routines. Residual mains noise was removed using a three-point 
running mean – equivalent to a low pass filter with a cut-off at 43 Hz. Eye blink artefacts 
were taken out through applying a template to the ballistic components of each eye blink 
recorded at Fp1 and then removing this component from the signals in the other channels 
after scaling for each channel with a least squares linear regression to leave residual EEG 
(Zhang et al., 2017). Other large artefacts, including muscle movement, were automatically 
replaced with missing values. The recordings were then checked visually, and any 
outstanding eye-blinks or muscle artefacts were then manually removed by the experimenter 
and replaced with missing values.  
2.6.3 Spectral Power Post-Processing. A 1-second Hanning window was applied to 
each trial. For the Stop trials, the 1-second Hanning window was applied 0.25 seconds before 
the presentation of the stop signal (auditory tone) through to 0.25 seconds after the stop signal 
had ended. On the Go trials, the Hanning window was centred on where the stop signal was 
delivered in the adjacent Stop trial. The cosine wave function of the Hanning window derives 
most power during the middle 0.5 seconds and the least during the leading and trailing 0.25 
seconds. It improves frequency resolution in the subsequent Fourier transform two-fold in 
comparison to a 0.5 second square window. A Fourier transform was then applied to the 
power spectrum, which was log transformed to normalise error variance before Stop/Go trials 
were averaged for each participant. 
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2.7 Statistical Analysis 
2.7.1 GCSR. GCSR for each participant was computed as a nominal linear (Stop, Go) 
x quadratic (short, medium, long SSD) orthogonal polynomial contrast. The average Go 
power was subtracted from the average Stop power for each SSD type to extract power 
specific to Stopping. Then the average of short and long SSD stop-specific power was 
subtracted from the medium SSD power to extract power specific to goal conflict. Maximum 
conflict was expected to occur to the medium SSD, as Going and Stopping were equally 
likely during this condition. In contrast, low levels of conflict were expected to occur during 
the short and long SSDs, with other factors (such as percent correct) tending to average to the 
value expected for medium SSD in the absence of conflict. Note that the F ratios obtained by 
ANOVA of these explicit GCSR values are identical to those that would be obtained for the 
Trial type[linear] x SSD[quadratic] interaction of the original data. 
2.7.2 Smoothing. A 3-point running mean across frequencies was used to smooth 
each participant’s GCSR to reduce the fluctuations in power between adjacent frequencies. 
This smoothing narrowed the frequency band by one data point at each end, reducing the 
initial 1-14Hz to my 2-13Hz band of interest (based on my expectation that power peaks 
would occur in the 4-12Hz range). As shown in Figure 2.2, the smoothing reduced spikes at 
particular frequencies and produced a clearer pattern of data. 
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Figure 2.2. Example of smoothing data. The dashed line represents the unsmoothed data. 
Note the volatile variation across frequencies, while the smoothed data (solid line) show a 
clearer form.  
 
2.7.3 Analysis of Variance. Analysis of GCSR was restricted to the F8 channel, as 
this is the only location where correlations between GCSR and trait anxiety have previously 
been found (Neo & McNaughton, 2011). It is also the site where the clearest results have 
previously been obtained (McNaughton et al., 2013; Neo & McNaughton, 2011; Shadli et al., 
2015). ANOVA was computed using the IBM SPSS Statistics Package 25 (IBM North 
America, New York, NY, USA). Factors included in this analysis were frequency (2-13Hz), 
block (1-3), and groups. For SJS participants, groups had 3 levels (high, medium, low); for 
the main patient analysis, groups had 3 levels (high STAI-T patients, low-STAI-T patients, 
and controls); and for analysis of DSM-IV-TR diagnoses, groups had 4 levels (GAD, GAD 
with concurrent MDD, SAD, and other). Frequency and blocks were automatically assessed 
for orthogonal polynomial components by SPSS. In the case of significant frequency 
components, the matching regression function was plotted over the graphs of the means to 
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been found to become unstable during SST (e.g., be high in one block and low in another). 
The fluctuation in GCSR across blocks is theorised to be caused by loss of motivation (Shadli, 
McIntosh, & McNaughton, 2019). Since GCSR is labile across the task, I analysed blocks to 
see whether GCSR differences between groups occur in a specific block or combination of 
blocks.  
2.7.4 Stepwise Regression. Trait scores from the STAI were used to separate SJS and 
patient groups into subgroups (see section 2.1.3). However previous studies have indicated 
that STAI-T may not be a pure measure of anxiety (e.g. Bieling et al., 1998; Grös, Antony, 
Simms, & McCabe, 2007). To investigate the discriminative validity of the STAI-T, I 
conducted four stepwise regression analyses using the SPSS. The factors included within this 
analysis were the personality measures of Neuroticism, PID-ANX, PID-DEP and STAI-T. 
Neuroticism, PID-ANX and PID-DEP were initially used as predictor variables for STAI-T 
scores. Separate regressions analyses were then conducted to investigate the relations 
between these measures and STAI-T. Significance was identified by p < 0.05.  
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Chapter 3: Results 
3.1 Chapter Overview 
The current chapter outlines the findings from my four separate analyses (noted 
previously in Chapter 2). The results from comparing GCSR across participants recruited 
from online Student Job Search (SJS) are presented first. I then describe the results 
comparing GCSR between DSM-IV-TR (APA, 2000) anxiety disorder diagnosed patients 
and healthy controls. The results from a series of multiple regression analyses are then 
presented, followed by the comparison of GCSR between patients with differing DSM-IV-TR 
(2000) anxiety disorder diagnoses.  
 In the first analysis, I compared the strength of GCSR between participants recruited 
from Student Job Search (SJS) using a mixed measures analysis of variance (ANOVA).  As 
outlined in Sections 1.10, I separated participants into groups and used ANOVA for my 
analysis because I was unable to derive a single number for GCSR. GCSR was compared 
between participants with nominally high, medium, and low levels of anxiety, as indexed by 
their State Trait Anxiety Inventory trait scores (STAI-T; Spielberger et al., 1983). 
Participants recruited from SJS were initially intended to act as controls for the patient 
sample; but due to the demographic differences and dissimilar recruitment methods for the 
SJS participants, I decided to analyse their data separately to avoid any sampling bias. 
Participants recruited from SJS were not assessed for anxiety disorder diagnoses during 
recruitment. Although none of the SJS participants explicitly reported experiencing clinically 
significant levels of anxiety, I found that a number of participants had trait anxiety scores that 
were quantitatively similar to groups of clinically anxious patients that had previously been 
reported in the literature. Therefore, I separated SJS participants into three groups using 
STAI-T scores.  
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In the second analysis, I investigated the difference in GCSR between DSM-IV-TR 
anxiety disorder diagnosed patients and age-matched controls. To produce a similar spread of 
participants as the SJS analysis, patients were separated into two groups (high and low) based 
on a median split using STAI-T scores. The third analysis explored whether the STAI-T 
includes measures of depression, as well as anxiety. A series of multiple regression analyses 
were conducted to see how much of the variations in STAI-T scores were explained by  
Neuroticism scores from the EPQ-R (Eysenck Personality Questionnaire-Revised; Eysenck & 
Eysenck, 1991), and Anxiety and Depressivity scores from the PID-5 (Personality Inventory 
for DSM-5; APA, 2013). In the final analysis, I compared the strength of GCSR between 
patients with different DSM-IV-TR (APA, 2000) anxiety disorder diagnoses. The purpose of 
this final analysis was to investigate the relationship between current anxiety disorder 
diagnoses and GCSR.  
 
3.2 Comparison of goal-conflict specific rhythmicity between student job search 
recruited participants with different trait anxiety scores 
A repeated measures ANOVA was conducted to investigate the variations in GCSR 
between three SJS participant groups (High STAI-T, Medium STAI-T and Low STAI-T 
groups). As noted in Sections 2.1.3, the High STAI-T group included participants with STAI-
T scores of 40 or above. Participants with STAI-T scores between 34 and 39 were included in 
the Medium STAI-T group, and participants with STAI-T scores 33 or below were placed in 
the Low STAI-T group.  
3.2.1 Exclusions. In total, 86 participants were recruited from online SJS (26 males 
and 60 females). Two males and five females were excluded before analysis due to noisy 
EEG recordings (missing values exceeded 10%). Of the remaining 79 participants, three were 
excluded from block 2, and eight were excluded from block 3 due to missing GCSR data.  
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3.2.2 Descriptive Statistics. Descriptive statistics for the participants’ gender, age, 
and personality questionnaire scores are presented in Table 3.1. The High STAI-T group had 
27 participants, the Medium STAI-T group included 24 participants, and the Low STAI-T 
group had 28 participants. On the whole, there were more female participants (69.6%) than 
male participants (30.4%). The mean age of the SJS participants was 21.8 years old. 
Participants in the High STAI-T group had the highest average of Neuroticism scores, 
followed by the Medium STAI-T group, and Low STAI-T group. The mean PID-5 Anxiety 
and PID-5 Depressivity scores were also highest in the High STAI-T participants, followed 
by the Medium, and then the Low group.  
 
Table 3.1 
Descriptive statistics for the SJS sample.  
 Gender    PID-5 
Group M:F Age STAI-T EPQ Neur ANX DEP 
High 5:22 18-29 (20.4) 48.2 11.3 23.0 27.1 
Medium 8:16 18-37 (23.3) 37.0 5.3 17.9 18.4 
Low 11:17 18-32 (21.8) 30.1 2.6 14.6 16.4 
Notes. Means and ranges for the different SJS groups separated by STAI-T scores. 
Abbreviation: M:F, number of male and female participants; Age, average age of 
participants in each group; STAI-T, Spielberger trait anxiety; Neur, EPQ Neuroticism; 
PID-5 Anxiety, DSM-5 Personality Inventory anxiety; and PID-5 Depressivity, DSM-5 
Personality Inventory depressivity. 
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3.2.3 Differences in goal-conflict specific rhythmicity. The average difference in 
GCSR at F8 between participants with High, Medium, and Low STAI-T scores was 
calculated separately for individual blocks (1, 2, and 3) and is shown in Figure 3.1.  
 
Figure 3.1. Frequency variation of Goal-Conflict Specific Rhythmicity (GCSR) obtained at F8 
from High, Medium, and Low STAI-T scoring groups. Blocks of trials are presented in a 
chronological order from the top of the figure. GCSR averaged across all three blocks are 
shown at the very bottom graph (note change in scale). The two standard error bars above 
each graph on the right represents the between subjects comparison. The single standard 
error bars shown on the data points represent the repeated measures comparison.  
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On average, patterns of GCSR appeared to be different across blocks. In block 1, 
positive GCSR was generally only observed in the Low STAI-T group. Blocks 2 and 3 
seemed to have fairly similar patterns of GCSR, with notable peaks between 7-9Hz and weak 
GCSR at the lower and higher ends. 
As shown in Figure 3.1, participants in the High STAI-T showed a different pattern of 
GCSR to the Medium and Low STAI-T groups in block 2, relative to blocks 1 and 3 (Group 
x Block[quad] x Frequency[order 4], F(2, 66) = 7.713, p < 0.001). The quadratic component 
of block indicates that there was a significant quartic (order 4) component of frequency in 
block 2, but not in blocks 1 and 3.  Post hoc ANOVA of the groups, found a difference in this 
interaction term between the High and Medium STAI-T groups (Group x Block[quad] x 
Frequency[order 4], F(1, 43) = 12.878, p = 0.001), but not between either the Medium and 
Low STAI-T (Group x Block[quad] x Frequency[order 4], F(1, 43) = 1.042, p = 0.313), or 
the High and Low STAI-T groups (Group x Block[quad] x Frequency[order 4], F(1, 43) = 
1.423, p = 0.239). The source of the quartic (order 4) component of frequency is shown in 
Figure 3.2. Given that there were only three blocks, the quadratic component of blocks is the 
equivalent of subtracting the average of blocks 1 and 3 from block 2. Figure 3.2 shows the 
frequency variation in this quadratic component. High STAI-T and Low STAI-T have very 
similar curves (as shown in Figure 3.2), with High STAI-T (solid curve shown in the figure) 
showing negative inflections at 2Hz and 11Hz, and a strong positive inflection at 6 – 7Hz. 
The Medium STAI-T group have an opposite curve (dashed curve shown in Figure 3.2). 
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Figure 3.2. Variation of GCSR across the 2-13Hz frequency range. The graph presents GCSR as the 
difference between block 2 and the average of blocks 1 and 3 for all three STAI-T groups. The thin 
black line represents a quartic trend line (curve with three inflections).  
 
Post hoc ANOVAs were conducted for each of the individual blocks using the same 
within-subjects factor (frequency, Hz), between-subjects factor (group, 3 levels), and 
measured variable (GCSR, log µV²). As previously shown in Figure 3.1, strong GCSR was 
observed between 2–4Hz in the High STAI-T group, before it decreased to 0 log µV
2
 at 7Hz 
through to 12Hz in block 1. The Medium STAI-T group had low GCSR (around 0 log µV
2
) 
between 2–8Hz, before peaking moderately to 0.06 log µV
2
 at 9Hz. After this peak, GCSR 
decreased to -0.12 log µV
2
 at 12Hz. GCSR for the Low STAI-T group appeared to have a 
broad, inverted U-like shape that ranged from approximately 3Hz to 11Hz. Overall, the Low 
STAI-T group appeared to have the most strongly positive GCSR in block 1. Despite these 
observations, there were no significant differences in GCSR variation across frequencies 
between the three groups (Group x Frequency[all trends], all F(2,76) < 1.227, all p > 0.299). 
Furthermore, there were no statistically significant differences in GCSR averaged across 
frequency between the three groups in this block (Group, F(2, 76) = 0.810, p = 0.449).  
In block 2, the High STAI-T group showed a peak of 0.11 log µV
2
 at 7Hz. The High 
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from the slight trough between 5–8Hz, the Medium STAI-T group appeared to have a 
relatively flat shape. The Low STAI-T group had moderately positive GCSR between 2–9Hz 
before it decreased at 10Hz. It appeared that the High STAI-T group had a different pattern of 
GCSR to the Medium group (Group x Frequency[order 4], F(2, 73) = 2.584, p = 0.082). 
While this difference did not reach statistical significance for this middle block, the variation 
was significant overall across between blocks (Group x Block[quad] x Frequency[Order 4], 
F(2, 66) = 7.713, p < 0.001). There was no significant overall difference in GCSR across 
frequency between the three groups in this block (Group, F(2,73) = 0.007, p = 0.993).  
In block 3, the High STAI-T group had a peak of 0.07 log µV
2
 at 7Hz and a smaller 
peak of 0.05 log µV
2
 at 3Hz. The Medium STAI-T group had a peak of 0.13 log µV
2
 at 7Hz, 
and appeared to have the most strongly positive GCSR in this block. GCSR for the Low 
STAI-T group was negative between 2-10Hz, before becoming positive in the higher 
frequencies. Visually, block 3 had the clearest separation between the groups, especially 
within the 4–9Hz range. There appeared to be some variation in GCSR between the High and 
Low STAI-T groups. The Low STAI-T group had almost an opposite curve to the High 
STAI-T group (Group x Frequency[order 6], F(2, 68) = 2.810, p = 0.067), however, this did 
not reach statistical significance. There were also no significant differences in GCSR 
averaged across frequency between the groups in this block (Group, F(2, 68) = 0.167, p = 
0.846).  
The bottom graph in Figure 3.1 shows GCSR averaged across blocks for the three 
different groups. The groups appeared to have similar patterns of GCSR, with positive GCSR 
at lower frequencies, especially between 5-9Hz, followed by negative GCSR at higher 
frequencies (Frequency[linear], F(1, 66) = 3.567, p = 0.063). In this graph, the High STAI-T 
group seemed to have slightly stronger GCSR between 6–8Hz compared to the other two 
groups.  
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3.3 Comparison of Goal-Conflict Specific Rhythmicity between anxiety disorder 
patients and healthy controls recruited from the community 
Participants recruited from online SJS in the first analysis were not assessed for any 
DSM-IV-TR (APA, 2000) anxiety disorder diagnosis. It was unclear whether participants in 
the High STAI-T group experienced clinically significant levels of anxiety and if the results 
from the first analysis were due to a true effect of high anxiety. To investigate the difference 
in GCSR between patients and healthy non-anxious individuals, a replication matching the 
form of the first analysis, but involving DSM-IV-TR (APA, 2000) anxiety disorder diagnosed 
patients was conducted. In this second analysis, patients were separated into two groups 
based on a median split of STAI-T scores. The groups were approximately equal in size to 
each other and to the sample of age-matched controls. Patients with STAI-T scores of 56 or 
above were placed into the High STAI-T patient group, while the remaining patients with 
STAI-T scores of 55 or below were placed into the Low STAI-T patient group. Participants 
recruited from the community reporting as being healthy were identified as controls.  
3.3.1 Exclusions. Sixty-one non-treated patients were recruited via various 
advertisement around Dunedin. However, eight were excluded before analysis due to noisy 
EEG (more than 10% missing values). Six participants in the control group were also 
excluded post-processing due to having STAI-T scores above the clinical cut-off score of 46.  
3.3.2 Descriptive Statistics. Descriptive statistics for patients with high STAI-T 
scores, patients with low STAI-T scores and controls are shown in Table 3.2. Overall, there 
were more female participants (80.7%) than male participants (19.3%). The average age of 
community recruited participants (patients and controls) was 34.5 years old. High Patients 
had the highest Neuroticism average, followed by Low patients, and then Controls. PID-5 
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Anxiety and PID-5 Depressivity scores were also highest in the High Patient group, followed 
by the Low Patient group, and then Controls. 
 
Table 3.2 
Descriptive statistics for the community recruited sample 
 Gender    PID-5 
Group M:F Age STAI-T EPQ Neur Anxiety Depressivity 
High Patient 6:20 34.0 61.3 17.8 30.4 37.0 
Low Patient 4:23 33.9 48.8 11.5 27.1 25.0 
Control 7:28 35.3 33.3 4.5 14.5 18.2 
Notes. Descriptive statistics for High Patient, Low Patient, and Control groups. 
Abbreviation M:F, number of male and female participants in the group; Age, mean age of 
participants per group; STAI-T, average Spielberger trait anxiety score; Neur, average 
EPQ Neuroticism score; PID-5 Anxiety, average DSM-5 Personality Inventory anxiety 
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3.3.3 Differences in goal-conflict specific rhythmicity. The average GCSR for High 
STAI-T patients, Low STAI-T patients, and Controls for individual blocks (1, 2, and 3) are 
shown in Figure 3.3.  
 
Figure 3.3. Goal Conflict Specific Rhythmicity (GCSR) recorded at F8 between 2-13Hz from 
patients with High STAI-T, Low STAI-T, and Controls. Block 1, 2, and 3 are presented in 
order from the top of the figure. GCSR averaged across all three blocks are shown at the 
very bottom (note change in scale). The two standard error bars above the graphs on the 
right represent the between subjects comparison. The single standard error bars on the data 
points on the left are for the repeated measure comparisons.  
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As seen above in Figure 3.3, the patients with low STAI-T scores appeared to have 
similar patterns of GCSR as Controls, with weak GCSR at lower frequencies and a positive 
peak between 7–12Hz. In block 3 however, patients with low STAI-T scores appeared to 
have an opposite curve, with a positive inflection between 2–7Hz, followed by slight negative 
inflection between 8–13Hz (Group x Block[linear] x Frequency[cubic], F(2, 76) = 2.972, p = 
0.057). Post hoc analysis showed that this cubic effect between blocks 1 and 3 was close to 
significance only in patients with low STAI-T scores (Block[linear] x Frequency[cubic], F(1, 
24) = 4.123, p = 0.054), and not in patients with high STAI-T scores (Block[linear] x 
Frequency[cubic], F(1, 23) = 0.301, p = 0.589) or controls (Block[linear] x Frequency[cubic], 
F(1, 29) = 0.088, p = 0.769). In comparison, patients with high STAI-T scores appeared to 
have a fairly similar pattern of GCSR across blocks, with stronger GCSR at low frequencies, 
and weaker GCSR at high frequencies.   
Similar to the previous section, post hoc ANOVAs were calculated for the individual 
blocks using the same within-subjects factor (frequency, Hz), between-subjects factor (group, 
3 levels), and measured variable (GCSR, log µV²). As seen in Figure 3.3, all groups had 
positive GCSR in block 1 that followed an inverted U-like shaped curve (Frequency[quad], 
F(1, 79) = 7.966, p = 0.006). The positive curve occurred between 4-9Hz for patients with 
high STAI-T scores, 7–11Hz for patients with low STAI-T scores, and 6–12Hz for controls. 
Patients with high STAI-T scores showed stronger GCSR in the lower frequencies and 
weaker GCSR in the higher frequencies, while the other two groups showed opposite curves 
(Group x Frequency[cubic], F(2, 79) = 4.906, p = 0.010). There were no significant 
differences in GCSR averaged across frequencies between the groups (Group, F(2, 79) = 
0.408, p = 0.666).   
In block 2, there was a tendency for GCSR to decrease with increasing frequency 
across all three groups (Frequency[linear], F(1, 83) = 9.031, p = 0.004). Patients with high 
ANXIETY BIOMARKER 51 
STAI-T scores had the strongest GCSR in the lower frequencies (2-4Hz). Patients with low 
STAI-T scores appeared to have stronger GCSR between 5–9Hz, before dropping at 10Hz. 
Controls had weakly positive GCSR between 2–5Hz, which dropped into the negatives after 
6Hz. The separation between the patient groups and the controls was the most visually 
distinct in this block, however, there was no significant variation in GCSR across frequencies 
between the groups (Group x Frequency[all trends], all F(2, 83) < 1.529, p > 0.223). The 
overall difference between the groups also did not reach statistical significance (Group, 
F(2,83) = 2.278, p = 0.109).  
In block 3, patients with high STAI-T scores appeared to almost have two peaks. The 
first peak was at 4Hz and the second one occurred at 8Hz. GCSR for patients with high 
STAI-T scores was positive between 2–10Hz before decreasing into the negatives from 11Hz 
onwards. Patients with low STAI-T scores had the strongest GCSR between 2–7Hz, with a 
peak of 0.12 log µV² at 4Hz. GCSR for this group gradually decreased to 0 log µV² after 8Hz. 
Controls had the strongest GCSR at 2Hz before it gradually decreased to -0.03 log µV² at 
5Hz. From 7Hz onwards, GCSR increased to form a peak at 11Hz for this group. The 
controls showed an opposite pattern of GCSR to the other two groups, with a negative 
inflection in the middle frequencies and a positive inflection at higher frequencies (Group x 
Frequency[cubic], F(2, 80) = 3.231, p = 0.045). There was no significant difference in GCSR 
averaged across frequency between the three groups (Group, F(2, 80) = 0.134, p = 0.874).  
The bottom graph in Figure 3.3 shows GCSR averaged across all blocks. Both patient 
groups appeared to have a broad inverted-U pattern between 3–10Hz. It appeared that GCSR 
for the High Patient group was marginally stronger, with a peak of 0.08µV² at 4Hz. After 
9Hz, GCSR for both patients with high and low STAI-T scores decreased towards 0 log µV². 
The controls had the weakest GCSR between 2-9Hz, with a broad U-shaped like curve and a 
trough of 0.00 log µV² at 5Hz. At higher frequencies, the control group had a positive curve 
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with a peak of 0.05 log µV² at 9Hz. Overall, patients with high and low STAI-T scores had 
similar patterns of GCSR, while the controls showed an opposite curve (Group x 
Frequency[cubic], F(2, 76) = 3.214, p = 0.010). Post hoc analyses demonstrated this cubic 
variation to be significant between patients with high STAI-T scores and controls (Group x 
Frequency[cubic], F(1, 55) = 4.111, p = 0.047) and patients with low STAI-T scores and 
controls (Group x Frequency[cubic], F(1, 57) = 5.047, p = 0.029), but not between patients 
with high and low STAI-T scores (Group x Frequency[cubic], F(1, 48) = 0.372, p = 0.545). 
There was no significant difference in GCSR averaged across frequency between the three 
groups (Group, F(2, 76) = 0.447, p = 0.642).  
 
3.4 Multiple regression analyses 
In the third analysis, I used multiple regression analyses to look at the contributions of 
neuroticism and depression on STAI-T scores. Neuroticism (EPQ-N), PID-5 Anxiety (PID-
ANX), PID-5 Depressivity (PID-DEP), and STAI-T scores from participants across both the 
first (i.e., SJS participants) and second (i.e., patients and controls) analyses were used for this 
analysis.  
 3.4.1 Descriptive Statistics. The combined sample of participants recruited from SJS 
and the community (i.e., patients and controls) was 167 participants. There were more 
females (75.4%) than males (24.6%). The mean age of all participants was 28.4 years old. 
Averaged STAI-T score was 42.6. The mean EPQ-N score was 8.2, the mean PID-ANX 
score was 20.8, and the averaged PID-DEP score was 23.8.  
3.4.2 Stepwise Regression. First, EPQ-N, PID-ANX, and PID-DEP scores were 
entered as predictors of STAI-T. EPQ-N, PID-DEP and PID-ANX explained approximately 
77% (r² = 0.765) of the variance in STAI-T (r = 0.874, F(3, 163) = 172.159, p < 0.001), with 
EPQ-N as the primary predictor, followed by PID-DEP, and then PID-ANX. EPQ-N alone 
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was found to account for 69.1% (r² = 0.691) of the variance in STAI-T scores (r = 0.831, F(1, 
162) = 360.254, p < 0.001). As shown in Table 3.3, PID-DEP was found to account for 
48.1% (r² = 0.481) of STAI-T scores, but 26.2% (r² = 0.262) of this variance was shared with 
EPQ-N. The PID-ANX was shown to account for 62.8% (r² = 0.628) of variance in STAI-T 
scores, but approximately 60% of this variance was shared with EPQ-N and PID-DEP. The 
unique variance of EPQ-N, PID-DEP and PID-ANX was 7.8% (r² = 0.078), 2.9% (r² = 0.029) 
and 2.2% (r² = 0.022), respectively.  
 
Table 3.3 
Predictors accounting for variance in STAI-T 
Prediction of STAI-T 





Shared variance 61.3% 
 
The high percentage of shared variance in the previous analysis shows that the 
contribution of PID-DEP and PID-ANX was covered by EPQ-N. I therefore conducted a 
stepwise regression without EPQ-N. PID-DEP and PID-ANX was significantly related to 
STAI-T (r = 0.828, F(2, 163) = 175.577, p < 0.001), accounting for approximately 69% of the 
variance (r² = 0.686). PID-ANX was the primary predictor, accounting for 62.7% (r² = 0.627) 
of the variance in STAI-T; PID-DEP accounted for 48.1% (r² = 0.481). The shared variance 
between PID-ANX and PID-DEP was 42.2% (r² = 0.422) and the unique variance of PID-
ANX and PID-DEP was 20.5% (r² = 0.205) and 5.8% (r² = 0.058), respectively.  
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Table 3.4 
Prediction of STAI-T with PID-ANX and PID-DEP as predictors 
Prediction of STAI-T 




Shared variance 42.2% 
 
In a separate analysis, EPQ-N and PID-ANX scores for each participant were entered 
as predictors for STAI-T (non-stepwise). As shown in Table 3.5, High EPQ-N and PID-ANX 
scores predicted higher STAI-T scores F(2, 163) = 222.308, p < 0.001 (r² = 0.735); however 
– as expected – the variance of PID-ANX was low (approximately 4%).   
 
Table 3.5 
Prediction of STAI-T with EPQ-N and PID-ANX as predictors 
Prediction of STAI-T 




Shared variance 58.3% 
 
A separate stepwise regression was conducted with PID-DEP and PID-ANX 
predicting EPQ-N. High PID-DEP and PID-ANX scores significantly predicted higher EPQ-
N (F(2, 162) = 156.644, p < 0.001), contributing to approximately 66% of the variance (r² 
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= .662). PID-ANX was the primary predictor of EPQ-N, accounting for 60.7% (r² = 0.607) of 
the variance, while PID-DEP accounted for 44.6% (r² = 0.446) of the variance. The two 
predictors shared approximately 39% (r² = 0.388) of the overall variance, with PID-ANX and 
PID-DEP having unique variance of 21.9% (r² = 0.219) and 5.8% (r² = 0.058), respectively.   
 
Table 3.6 
Prediction of EPQ-N with PID-ANX and PID-DEP as predictors 
Prediction of STAI-T 




Shared variance 38.8% 
 
3.5 Comparison of goal-conflict specific rhythmicity between patients with different 
anxiety disorder diagnoses 
For the final analysis, a repeated measures ANOVA was performed to investigate the 
variations in GCSR between patients with different DSM-IV-TR (APA, 2000) anxiety 
disorder diagnoses. As previously outlined in Sections 2.1.3, patients were separated into four 
groups based on their primary Mini International Neuropsychiatric Interview (MINI; 
Lecrubier et al., 1997) diagnosis. The four groups included patients diagnosed with 
Generalised Anxiety Disorder (GAD), GAD and Major Depressive Disorder (MDD), Social 
Anxiety Disorder (SAD), and a pool of other anxiety disorder diagnoses (e.g., panic disorder 
and post-traumatic stress disorder).  
3.5.1 Descriptive Statistics. The descriptive statistics for patients diagnosed with 
GAD, GAD and MDD, SAD, and other anxiety disorder diagnoses are presented in Table 3.7. 
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Overall there were more female participants (82.8%) than male participants (18.2%) in this 
analysis. The mean age of patients were 33.9 years old. Patients diagnosed with SAD 
reported the highest STAI-T scores, followed by patients diagnosed with GAD and MDD, 
patients diagnosed with GAD, and patients diagnosed with other anxiety disorder diagnoses. 
EPQ Neur, PID-ANX and PID-DEP was also the highest in patients diagnosed with SAD, 
followed by patients diagnosed with GAD and MDD, patients diagnosed with GAD, and 
patients diagnosed with other anxiety disorder diagnoses.  
 
Table 3.7. 
Descriptive Statistics for the patients with different DSM-IV-TR diagnoses 
 Gender    PID-5 
Group M:F Age STAI-T EPQ Neur Anxiety Depressivity 
GAD 1:15 37.6 52.9 13.1 29.6 27.3 
GAD+MDD 3:13 29.7 56.4 15.1 28.5 31.1 
SAD 5:9 34.4 59.7 17.5 30.0 36.0 
OTHER 2:8 33.3 51.3 14.5 26.2 30.4 
Notes. Averages for the different patient groups split by primary DSM-IV-TR diagnoses. 
Abbreviation: GAD, Generalised Anxiety Disorder; GAD+MDD, Generalised Anxiety Disorder 
with concurrent Major Depressive Disorder; SAD, Social Anxiety Disorder; OTH, other DSM-IV-
TR anxiety disorder; M:F, number of male and female participants; Age, average age of 
participants in each group; STAI-T, Spielberger trait anxiety; Neur, EPQ Neuroticism; PID-5 
Anxiety, DSM-5 Personality Inventory anxiety; and PID-5 Depressivity, DSM-5 Personality 
Inventory depressivity 
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3.5.2 Differences in strength of goal-conflict specific rhythmicity. Figure 3.4 
presents averaged GCSR for patients primarily diagnosed with GAD, GAD and MDD, SAD, 
and other anxiety disorder diagnosis in the 2–13Hz range across three blocks.  
 
Figure 3.4. The frequency variation of averaged GCSR at F8 taken from patients with 
primary diagnoses of pure GAD, GAD with concurrent MDD, SAD, and other diagnoses. The 
shaded grey area represents GCSR from the control group for comparison purposes; 
controls were not included in the group analysis. Blocks 1, 2, and 3 are presented in a 
chronological order from the top of the figure. GCSR averaged across all three blocks is 
presented at the very bottom. The two standard error bar above each the graphs represent 
the between subjects comparison. The single standard error bar on a data point at the left 
represents the repeated measures comparison.  
ANXIETY BIOMARKER 58 
As shown in Figure 3.4, patterns of GCSR appeared to be different across blocks for 
each diagnosis group. Patients with GAD and other anxiety disorder diagnoses seemed to 
have fairly similar GCSR to controls in block 1, with weak GCSR at lower frequencies and a 
positive inflection at higher frequencies. However, in block 3, patients with GAD and other 
anxiety disorder diagnoses appeared to have similar GCSR to SAD patients, with a positive 
inflection around 4–5Hz, followed by weaker GCSR at higher frequencies (Group x 
Block[lin] x Frequency[cubic], F(3, 48) = 2.661, p = 0.059). Patients with comorbid GAD 
and MDD had noticeably stronger GCSR than the other groups in block 2, compared to 
blocks 1 or 3, with strongly positive GCSR at lower frequencies that decreased with 
increasing frequency (Group x Block[quad] x Frequency[linear], F(3, 48) = 5.145, p = 0.004). 
Post hoc ANOVAs of the individual patient groups found a significant linear effect in block 2, 
relative to blocks 1 and 3, in patients with comorbid GAD and MDD (Block[quad] x 
Frequency[lin], F(1, 13) = 33.203, p < 0.001), but not in patients with GAD (Block[quad] x 
Frequency[lin], F(1, 14) = 0.074, p = 0.789), SAD (Block[quad] x Frequency[lin], F(1, 13) = 
0.028, p = 0.869), or other anxiety disorder diagnoses (Block[quad] x Frequency[lin], F(1, 8) 
= 2.406, p = 0.159). 
Post hoc ANOVAs were carried out for the individual blocks. In block 1, patients 
with GAD had an inverted-U curve, with a peak of 0.10 log µV² at 7Hz. SAD patients 
appeared to have a similar curve, with a peak of 0.09 log µV² at 6Hz (Frequency[quad], 
F(1,51) = 4.298, p = 0.043). GAD patients with comorbid MDD had relatively flat GCSR, 
with a slight positive slope between 2–6Hz. Patients with other anxiety disorder diagnoses 
had the strongest GCSR at 2Hz, before it formed a trough at 6Hz. Despite patients with other 
anxiety disorder diagnoses appearing to have distinct GCSR, there were no significant 
variations in GCSR across frequencies between the groups (Group x Frequency[all trends], 
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all F(1, 51) < 1.908, p > 0.140). There were also no significant differences overall between 
the groups (Group, F(3, 51) = 0.904, p = 0.446).   
In block 2, patients with GAD and MDD had strong positive GCSR in the lower 
frequencies that decreased with increasing frequency. Patients with pure GAD had relatively 
weak GCSR with a slight trough at 10Hz. Apart from the slight negative inflection between 
7–9Hz, SAD patients appeared to have relatively flat GCSR. Patients with other anxiety 
disorder diagnoses had the weakest GCSR at 2Hz, but it positively fluctuated with increasing 
frequency from 5Hz onwards. Patients with comorbid GAD and MDD had significantly 
different GCSR to the other groups, with strong GCSR between 2-9Hz that sloped 
downwards with increasing frequency (Group x Frequency[linear], F(1, 50) = 4.661, p = 
0.006), however, there were no significant differences in GCSR averaged across frequency 
between the groups (Group, F(3, 50) = 1.104, p = 0.356).  
In block 3, patients with GAD and other anxiety disorder diagnoses had positive 
GCSR at lower frequencies followed by an U-shaped like curve at higher frequencies 
(Frequency[cubic], F(1, 49) = 4.708, p = 0.035). Patients with comorbid GAD and MDD had 
positive GCSR at 2Hz before it dropped to -0.02 log µV² at 5Hz. GCSR increased for this 
group to form a peak of 0.08 log µV² at 8Hz before a negative inflection at 10Hz. SAD 
patients appeared to have a notable peak of 0.17 log µV² at 5Hz which steeply declined 
before levelling out from 7Hz; GCSR for this group decreased slightly from 10Hz onwards. 
Patients with GAD, SAD, and other anxiety disorder diagnoses showed similar patterns of 
GCSR, while patients with GAD and MDD had an opposite curve to the GAD patients. 
However, GCSR variation across frequency did not reach statistical significance (Group x 
Frequency[all trends], all F(1, 49) < 2.211, p = 0.099). There were also no significant 
differences in GCSR averaged across frequencies overall (Group, F(3, 49) = 0.225, p = 
0.878).  
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The bottom graph on Figure 3.4 shows GCSR averaged across all blocks for the four 
diagnostic groups. On average, GCSR was positive for all patient groups (Intercept, F(1, 49) 
= 8.599, p = 0.005). All DSM-IV-TR anxiety disorder diagnosis groups appeared to have 
stronger GCSR than controls between 2-8Hz. Patients diagnosed with GAD had a small U-
shaped curve between 2-5Hz with a peak of 0.06µV². This was followed by a relatively flat 
line between 6-8Hz, before GCSR decreased to -0.03 log µV² at 10Hz. Patients with 
comorbid GAD and MDD had relatively flat GCSR that decreased with increasing frequency. 
SAD patients had an inverted U-like shaped curve between 2-7Hz, with a peak of 0.11 log 
µV² at 5Hz. From 8Hz onwards, GCSR decreased for this group. Patients with other 
diagnoses appeared to almost have an opposite pattern of GCSR to SAD patients, with 
shallow U-shaped curve ranging between 2-7Hz, followed by a broad inverted U-shaped 
curve (Group x Frequency[cubic], F(3, 48) = 2.311, p = 0.088). No notable differences were 
otherwise observed between the different diagnosis groups when GCSR was averaged across 
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Chapter 4: Discussion 
4.1 Summary of the hypotheses and results 
The aim of this thesis was to investigate the clinical validity of a theoretically derived 
anxiety biomarker, goal-conflict specific rhythmicity (GCSR), within samples of participants 
recruited from Student Job Search (SJS) with different STAI-T scores and patients diagnosed 
with Diagnostic and Statistical Manual, 4th edition text-revised (APA, 2000) ‘anxiety 
disorders’. I hypothesised that: (1) participants experiencing high levels of anxiety, indexed 
by their STAI-T scores, would show increased GCSR; (2) GCSR would be higher across a 
heterogeneous group of patients with DSM-IV-TR anxiety disorder diagnoses compared to 
controls; and (3) no specific DSM-IV-TR (APA, 2000) anxiety disorder diagnosis would be 
linked to strong GCSR.  
In the first analysis, I compared GCSR between participants recruited online through 
SJS with ‘High’, ‘Medium’ or ‘Low’ STAI-T scores. On average, participants in the High 
STAI-T group produced slightly stronger GCSR than participants in the Medium and Low 
STAI-T groups. The difference in GCSR between the High STAI-T and the other two groups 
was particularly prominent in block 2 of the SST (see Figure 3.1). In this block, the High 
STAI-T group produced a positive peak between 7-9Hz, while the Medium and Low STAI-T 
groups showed relatively weak GCSR. The variation in GCSR between the High STAI-T and 
Medium STAI-T was significant in block 2, relative to blocks 1 and 3; however, no 
significant variation was found between the High STAI-T and Low STAI-T groups.  
In the second analysis, I compared GCSR between DSM-IV-TR (APA, 2000) anxiety 
disorder diagnosed patients and age-matched controls. To balance group size and match the 
form of the first analysis (i.e., have three groups with high, medium, and low levels of 
anxiety), I split the patient sample into two groups using a median split of STAI-T scores. 
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The median split resulted in DSM-IV-TR (APA, 2000) anxiety disorder diagnosed patients 
with STAI-T scores of 56 or above to be the ‘patients with high STAI-T score’ group and 
patients with STAI-T scores of 55 or below to be the ‘patients with low STAI-T score’ group. 
As shown in Figure 3.3, both patient groups showed stronger GCSR than controls in blocks 2 
and 3. The difference in GCSR between the patient groups and controls was significant in 
block 3 and when GCSR was averaged across all blocks. Despite SJS participants with higher 
STAI-T scores producing stronger GCSR than students with lower STAI-T scores in the first 
analysis, no significant differences were found between patients with high STAI-T scores and 
patients with low STAI-T scores in this analysis.  
The difference in GCSR between groups with high anxiety and low anxiety from the 
first and second analyses are presented in Figure 4.1. I subtracted GCSR of low-anxious 
participants (i.e., Low STAI-T SJS group and controls) from high-anxious participants (i.e., 
High/Medium SJS STAI-T group and patients with high/low STAI-T scores) to produce the 
curves in this figure; this was done to make the variations in GCSR between the groups 
appear clearer. Since high-anxious participants produced strong GCSR in blocks 2 and 3, I 
averaged GCSR across these two blocks. For visual comparison purposes, the inverted 
difference in GCSR between participants administered anxiolytic drugs and placebo from 
Shadli and colleague’s (2015) study is also shown (data re-analysed by Neil McNaughton, 
obtained through personal communications, December 2019). To make the trends appear 
clearer, a 3-point smoothing was applied to the data (frequency range shortened from 2-13Hz 
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Figure 4.1. Variations in GCSR between high-anxious and low-anxious participants from the 
first and second analysis, averaged across blocks 2 and 3 of the SST. The grey bold line 
represents the difference in GCSR between High STAI-T and Low STAI-T SJS participants, 
while the dashed grey line represents the variation between Medium and Low STAI-T 
participants from the first analysis (see Figure 3.1 for the raw GCSR power curves). The 
black solid line represents the difference in GCSR between patients with High STAI-T scores 
and controls from the second analysis. The black dashed line represents the variation in 
GCSR between patients with Medium and Low STAI-T scores (see Figure 4.1 for the raw 
GCSR curves). The dotted line represents the inverted difference in GCSR between healthy 
participants administered anxiolytic drugs and participants given placebo. GCSR data for the 
drug and placebo groups were taken from Shadli et al. (2015) and re-analysed by Neil 
McNaughton (obtained through personal communication, December 2019). It is important to 
note that the values for this drug-placebo GCSR curve was halved before plotting for scaling 
purposes.  
 
In the third analysis, I performed a series of multiple regression analyses using 
Anxiety and Depressivity scores from the Personality Inventory for DSM-5 (APA, 2013), 
Neuroticism scores from the EPQ-R (Eysenck Personality Questionnaire-Revised; Eysenck & 
Eysenck, 1991) and STAI-T scores. I used multiple regression analyses to investigate 
whether the STAI-T measures aspects of depression, as well as anxiety. Neuroticism, PID-
ANX, and PID-DEP scores were found to explain approximately 77% of the variance in 
STAI-T scores. PID-DEP was found to account for approximately 48% of the variation in 
STAI-T scores, with 45.2% of this variation being shared with the other predictors.    
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For the fourth analysis, I investigated the variation in GCSR between patients with 
different primary DSM-IV-TR (APA, 2000) anxiety disorder diagnosis. The analysis 
involved four groups, with primary diagnoses of: Generalised Anxiety Disorder (GAD), 
GAD and Major Depressive Disorder (MDD), Social Anxiety Disorder (SAD), and a pool of 
other anxiety disorder diagnoses (e.g., panic disorder). My analysis showed patients with 
GAD and MDD to produce very strong GCSR between 2-4Hz in block 2. The pattern of 
GCSR produced by patients with GAD and MDD was significantly different from the other 
three diagnosis groups. Patients diagnosed with SAD also appeared to have increased GCSR 
in block 3, but no significant differences were found between patients with SAD and the 
other diagnosis groups.  
 
4.2 GCSR was increased in students with high STAI-T 
Students with high STAI-T scores generally produced stronger GCSR than students 
with medium and low STAI-T scores. These findings support my first hypothesis that 
individuals experiencing high levels of ‘anxiety’ would show increased GCSR. The results 
are also consistent with previous GCSR research linking high STAI-T scores with stronger 
GCSR (Neo & McNaughton, 2011; Shadli et al., 2015). While the STAI-T is not a complete 
measure of anxiety (see Sections 4.3), there is a strong link between high STAI-T scores and 
anxiety disorder diagnoses (Oei, Evans, & Crook, 1990). Furthermore, researchers have 
demonstrated STAI-T to have a high degree of reliability and validity (Bieling et al., 1998; 
Julian, 2011). My findings therefore suggest that GCSR represents a neural process 
associated with some form of clinical anxiety.  
The results in block 2 of my analysis are mostly consistent with the work of McIntosh 
(2017), who compared GCSR between students with STAI-T scores above 45 and 
participants with STAI-T scores below 44 (her data are included in the current data set). She 
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reported participants with STAI-T scores above 45 to have slightly stronger GCSR than 
participants with lower STAI-T scores in blocks 2 and 3. Compared to her results though, my 
High STAI-T group did not show increased GCSR in block 3 (see Figure 3.1). The lack of 
increased GCSR in this block may be due to my High STAI-T group having a lower STAI-T 
cut-off score. As noted in Sections 2.1.3, the SJS sample was separated into three groups, 
using STAI-T scores, with the purpose of balancing group size. Due to the large number of 
participants with STAI-T scores within the lower range, the split resulted in the High STAI-T 
group including students with STAI-T scores within the normative population range. The 
standard sum score of STAI-T within a sample of anxiety disorder diagnosed patients is 
identified to be between 46 and 61 (Durham et al., 1994; Fisher & Durham, 1999); the cut-off 
score for my High STAI-T group was 40. Given that GCSR in my analyses are averaged 
across groups, it is likely that participants in the High STAI-T group with STAI-T scores in 
the normal range weakened the GCSR average.  
While the results from my first analysis point at GCSR being a neural process related 
to clinical anxiety, students in the SJS sample were not assessed for DSM-IV-TR anxiety 
disorder diagnoses during recruitment. For this reason, it is unclear whether participants in 
the High STAI-T group actually had clinically significant levels of anxiety. Thus, the link 
between GCSR and clinical anxiety can only be speculated from the findings in this analysis. 
 
4.3 Goal-conflict specific rhythmicity among clinically diagnosed patients 
Patients with a pathological BIS are predicted to generate high GCSR, whereas 
individuals with pathological Fight-Flight-Freeze System (FFFS), despite showing similar 
symptoms to patients with a hyper-reactive BIS, are expected to produce weak GCSR 
(McNaughton & Corr, 2016). Since pathological fear (i.e., FFFS) and anxiety (i.e., BIS) are 
classified together as ‘anxiety disorders’ in the DSM-IV-TR (APA, 2000), I predicted that my 
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heterogeneous sample of anxiety disorder patients would include patients with high and 
normal (relative to controls) GCSR. However, since the sample of clinically diagnosed 
patients are more likely to involve patients with pathological BIS, I hypothesised that DSM-
IV-TR (APA, 2000)  anxiety disorder patients, as a group, would produce a stronger GCSR 
than healthy controls.  
In line with my second hypothesis, DSM-IV-TR anxiety disorder diagnosed patients 
produced stronger GCSR than age-matched controls across blocks 2 and 3. As shown in 
Figure 4.1, both patient groups tended to produce stronger GCSR between 3-8Hz. The pattern 
of GCSR from my patient groups appeared to be different from Shadli et al. (2015) drug-
placebo group, but this might be due to my analysis including older DSM-IV-TR anxiety 
disorder diagnosed patients instead of younger non-anxious students. Patients diagnosed with 
DSM-IV-TR ‘anxiety disorders’ produced peaks at lower frequencies (4-5Hz) compared to 
SJS students (7-8Hz). Goal-conflict specific rhythmicity has typically been reported at 
frequencies above 5Hz; however, participants in these studies were all students without 
DSM-IV-TR anxiety disorder diagnoses. My current results suggest that patients 
experiencing clinically significant levels of anxiety may produce peaks at lower frequencies 
compared to non-patients. While more research is needed with a larger sample of patients, 
these findings have valuable implications for GCSR as a biomarker for anxiety in the future.  
The variation in GCSR between patients and controls was consistent with the results 
of McIntosh (2017), who also found DSM-IV-TR anxiety disorder diagnosed patients to have 
stronger GCSR than SJS participants with STAI-T scores below 45. In her analysis, McIntosh 
(2017) found DSM-IV-TR anxiety disorder diagnosed patients to have increased GCSR 
between 5-8Hz in block 2 and strong GCSR across 5-11Hz in block 3. Compared to my 
analysis though, the variation in GCSR between her patient and control group was not 
significant. One possible reason for this might be because her patients and control 
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participants were recruited using different methods. The control group in her analysis were 
recruited through an online advertisement on the SJS website for casual work, while her 
patients were recruited through the community via multiple sources of advertisements. 
Patients with DSM-IV-TR anxiety disorder diagnoses recruited from the community also 
appeared to be older than students recruited through SJS. Given that brain structures change 
with age (Albaugh et al., 2017), it is possible that the age difference between her groups also 
affected the results. In my analysis, I tried addressing these potential sampling biases by 
recruiting older participants for the control group, using similar methods as the patient sample. 
The consistent, but stronger differences observed between my patients and controls suggests 
that DSM-IV-TR anxiety disorder diagnosed patients do have increased GCSR.  
 No significant differences in GCSR were found between patients with high STAI-T 
scores and patients with low STAI-T scores (see Figure 3.2). These results are somewhat 
surprising given that students reporting higher STAI-T scores produced stronger GCSR in the 
first analysis. However, the literature on the relationship between STAI-T scores and GCSR 
suggests that despite a positive link between the two, STAI-T scores do not strongly predict 
GCSR power. Previous positive correlations reported between STAI-T scores and GCSR 
have been statistically weak. In Neo and McNaughton (2011) study, GCSR power between 7-
8Hz was found to predict higher STAI-T scores, but it only accounted for approximately 2% 
of the unique variance. Shadli et al. (2015) also reported positive relations between STAI-T 
scores and GCSR in blocks 1 and 3 of the SST but the correlations were not significant. 
Instead, GCSR is more strongly predicted by the shared variance of EPQ-N and STAI-T (Neo 
& McNaughton, 2011). The results from my analysis and previous research indicate that 
STAI-T measures an aspect of trait anxiety related to GCSR, but it does not represent GCSR 
completely.   
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 The STAI-T itself is not a pure measure of anxiety. I found Neuroticism scores from 
the EPQ-R (Eysenck Personality Questionnaire-Revised; Eysenck & Eysenck, 1991), 
Anxiety scores from the PID-5 (APA, 2013), and Depressivity scores from the PID-5 (APA, 
2013) to account for approximately 77% (r² = 0.765) of variance in STAI-T scores. 
Individually, EPQ-N, PID-ANX, and PID-DEP contributed to approximately 69.1%, 62.8%, 
and 48.1% of the variance in STAI-T, respectively. Strong relations between EPQ-N and 
STAI-T scores were expected, considering that neuroticism (a tendency to experience 
negative affect; Watson & Clark, 1984) is a risk factor for a range of internalising disorders, 
including anxiety (Ormel et al., 2013). It was also expected that PID-ANX would strongly 
predict STAI-T because they both measure aspects of anxiety defined by the DSM (APA, 
2013). While the unique variance was small (approximately 2%), PID-DEP was also found to 
predict STAI-T, demonstrating that STAI-T includes indexes of depression, as well as 
anxiety. My findings are consistent with previous research that showed the STAI-T to be 
constructed of questions that assess anxiety and depression (Bados, Gómez-Benito, & 
Balaguer, 2010; Bieling et al., 1998; Grös et al., 2007). Given that participants with higher 
STAI-T do generally produce stronger GCSR (see the stacking-like effect in Figure 4.1), it is 
possible that GCSR may reflect a process related to both anxiety and depression. This 
suggestion is further discussed in Sections 4.5.  
 
4.4 The unexpected finding in block 1 
In both analyses, participants with low anxiety (i.e., Low STAI-T group and controls) 
showed stronger GCSR than participants with high anxiety (i.e., High STAI-T group and 
patients) in block 1 (see Figures 3.1 and 3.3). The pattern of GCSR in block 1 is contrary to 
the BIS theory (Gray & McNaughton, 2000; McNaughton, 2014; McNaughton & Corr, 2004) 
and also contrasts with the positive correlation Shadli et al. (2015) found between GCSR and 
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EPQ-N in this block. One possible explanation for the results in block 1 is that participants 
with high and low anxiety adapted differently to the task. High STAI-T students and patients, 
due to their BIS sensitivity, may have produced strong anticipatory goal-conflict to the Go 
and Stop trials in block 1. As outlined in Sections 2.7.1., GCSR is calculated by subtracting 
the average Go-power from the average Stop-power, and then subtracting the average Stop-
Go power difference between the short and long Stop-Signal Delay (SSD) from the 
intermediate SSD. Given that GCSR is calculated using stop-specific power (i.e., Stop-Go 
power), high Go-power would result in weak stop-specific power, and so weak GCSR. In 
comparison, participants with low anxiety may have shown increased GCSR because they did 
not experience anticipatory goal-conflict on the Go trials (i.e., greater Stop-Go difference).  
The unexpected results were likely only observed in block 1, because anticipatory 
goal-conflict occurs when the task is novel (Harper, Malone, & Iacono, 2017; Wintink, 
Segalowitz, & Cudmore, 2001). Participants with high anxiety likely showed increased 
GCSR in the later blocks because they adapted to the task situation, and so produced weaker 
anticipatory goal-conflict to the Go trials in blocks 2 and 3 (i.e., stronger GCSR). In 
comparison, participants with low anxiety likely produced weaker GCSR in blocks 2 and 3 
because they habituated to the goal-conflict (i.e., produced weaker Stop-power). The 
explanations for the findings in block 1 noted in this section are hypothetical. In the current 
thesis, I was unable to analyse the difference in Go-power between participants with high and 
low anxiety due to time constraints. Given that this pattern of GCSR has been observed 
consistently in block 1 across different samples (McIntosh, 2017), it would be interesting to 
investigate the Go and Stop-power separately across blocks in the future.  
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4.5 Goal-conflict specific rhythmicity among patients with different anxiety disorder 
diagnoses 
Symptoms of ‘anxiety disorders’ can arise from either a symptomatic (i.e., hyper-
active) or a syndromal (i.e., hyper-reactive) neural system (McNaughton & Corr, 2016). 
Given that current diagnostic systems (APA, 2000; WHO, 2018) classify disorders based on 
symptoms rather than biomarkers, I predicted that there would be no links between DSM-IV-
TR (APA, 2000) anxiety disorder diagnoses and high GCSR. If there are any relations though, 
I expected that patients diagnosed with GAD, who are reported to have the highest response 
rate to anxiolytic drugs (Huh et al., 2011), would produce stronger GCSR than the other 
DSM-IV-TR (APA, 2000) anxiety disorder  diagnosis groups.   
 Contrary to my third hypothesis, I found significant variations in GCSR between 
patients with different primary DSM-IV-TR anxiety disorder diagnoses. In block 2, patients 
diagnosed with GAD and MDD produced strong positive GCSR between 2-4Hz that 
decreased with increasing frequency. The pattern of GCSR was significantly different from 
the other three groups, which appeared to have weak GCSR at lower frequencies. Patients 
diagnosed with SAD, GAD, and other diagnoses also showed strong GCSR between 3-6Hz in 
block 3, different from patients with GAD and MDD. These findings imply that despite the 
DSM-IV-TR (APA, 2000) classifying ‘anxiety disorders’ based on symptoms, their anxiety 
disorder diagnoses may not be as inaccurate as I initially predicted. The present results also 
hint at the possibility that the pattern of GCSR across blocks could be used to identify 
different types of anxiety disorder diagnosis in the future; for example, strong GCSR at low 
frequencies in block 2 could indicate GAD and MDD. A larger sample of patients with 
different DSM-IV-TR (APA, 2000) anxiety disorder diagnoses is required though to test this 
suggestion.  
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The BIS theory is founded upon the action of anxiolytic drugs (Gray & McNaughton, 
2000; McNaughton, 2017; McNaughton & Corr, 2004; Shadli et al., 2015). Goal-conflict 
specific rhythmicity is proposed to be a human biomarker for anxiety because it is reduced by 
all types of anxiolytic drugs and is not affected by drugs that alleviate symptoms of panic, 
phobia, or depression (McNaughton et al., 2013; Shadli et al., 2015). Since anxiolytic drugs 
reduce GCSR, I expected patients who are generally responsive to these drugs would show 
strong GCSR (i.e., patients diagnosed with GAD). Instead, patients diagnosed with GAD and 
MDD, who are reported to have low response rates to anxiolytics, produced very high GCSR 
(Coplan, Aaronson, Panthangi, & Kim, 2015). One possibility for my results is that anxiety 
and depression are strongly interlinked and chronic anxiety results in the emergence of 
depression.  
McNaughton and Corr (2016) previously suggested that anxiety and depression can 
co-occur together, even without either traits being pathological; for example, depressive 
behaviours are commonly observed alongside anxiety-related reactions in young animals that 
are separated from their parent (i.e., separation distress). Animals separated from their parents 
initially exhibit anxiety-related behaviours (e.g., walking around, crying), but after some time 
they become withdrawn and still (Harris, 1989; Watt & Panksepp, 2009). The initial anxiety 
is proposed to be adaptive in the short-term, because anxiety-related behaviours (e.g., 
walking around) increases the chances of reuniting with the parent (McNaughton & Corr, 
2016). In the long term however, the depressed state is viewed to be more adaptive, because 
it increases the chances of survival through conserving energy (Panksepp & Watt, 2011). The 
depressed state also reduces anxiety-related behaviours (e.g., crying) that can cause harm 
(e.g., attract predators in the wild; Watt & Panksepp, 2009).  
According to Nesse (2000), depression evolved for the purpose of preventing 
organisms from pursuing unreachable goals; for example, it is safer to stay inside during a 
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blizzard than to scavenge for food. McNaughton and Corr (2016) further argued that stress, 
depression, and anxiety likely evolved together to resolve goal-conflicts that occur both in the 
short and long-term. Depression is proposed to resolve goal-conflict in the long-term by 
reducing neural activity related to reward and suppressing goal pursuit (Panksepp & Watt, 
2011; Watt & Panksepp, 2009). Findings from a recent study published by Cavanagh, 
Bismark, Frank, and Allen (2019) supports this suggestion. Cavanagh et al. (2019) looked at 
the relationship between symptoms of depression and EEG in response to rewards and 
punishment. Two participant groups, controls with low Beck Depression Inventory (BDI; 
Beck, Epstein, Brown, & Steer, 1988) scores and participants with high BDI scores, 
performed a probabilistic learning task while having their EEG recorded. During the learning 
phase, participants were required to choose a character from sets of random Japanese 
Hiragana pairs; each character was associated with a specific probability of receiving a 
‘correct’ or ‘incorrect’ response (e.g., A/B – 80%/20% of receiving ‘correct’ feedback). In 
the test phase, all possible sets of pairs were presented to the participant, but no feedback was 
given. The accuracy of choosing the character with the highest ‘correct’ possibility was 
defined as reward-seeking, while the accuracy of avoiding the character with the lowest 
‘correct’ possibility (i.e., highest ‘incorrect’ possibility) was defined as punishment 
avoidance. Cavanagh and colleagues (2019) found significant negative correlations between 
symptoms of depression and reward-related positivity event-related potential (ERP) during 
reward seeking. Reward-related positivity is an EEG trait commonly observed in the delta 
band, approximately 300ms after presentation of a rewarding stimuli (Proudfit, 2015). Studies 
with gambling tasks (with and without monetary gain) have found that the amplitude of 
reward-related positivity is higher when the outcome is more positive than negative (Tunison, 
Sylvain, Sterr, Hiley, & Carlson, 2019). Based on the significant negative correlations 
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between depression and reward positivity ERP, Cavanagh et al. (2019) concluded that 
depression suppresses activity in a neural system that is linked to reward processing.  
In regards to the two-dimensional theory of defence (McNaughton & Corr, 2004), 
depression seems to decrease activity in the BAS (Behavioural Activation System). As 
discussed in Chapter 1, simultaneous activation of the BAS and FFFS results in the activation 
of the BIS (McNaughton & Corr, 2008). The BIS is thought to solve goal-conflict by 
increasing activity in the FFFS (i.e., increasing avoidance), and so it seems reasonable to 
assume that depression solves long-term goal-conflict by reducing BAS activity (i.e., 
decreasing approach towards unobtainable goals and promoting withdrawal). Anxiety is also 
likely to contribute to the development of depression through the release of stress hormones. 
As discussed in Chapter 1, anxiety is associated with the release of cortisol (Korte, 2001). 
Since stress has a critical role in the emergence of depression (see Hammen, 2005 for review), 
it is likely that chronic anxiety causes stress-sensitive individuals to develop depression. 
Given the extensive links between anxiety and depression, it may be common for patients 
with very strong GCSR (i.e., pathological BIS) to experience symptoms of depression.   
 The results from my fourth analysis shows that GCSR is high in patients who are 
unresponsive to anxiolytic drugs. Treatment resistant patients (n = 5) from a separate 
ketamine study (data provided by Shadli, 2019, personal communication), also produced very 
strong GCSR in block 2. The GCSR produced by treatment resistant patients was stronger 
than the GCSR generated by patients diagnosed with GAD and MDD. As shown in Figure 
4.2, the pattern of GCSR from treatment resistant patients appeared to resemble the GCSR 
curve of High STAI-T participants from the first analysis. Although GCSR is theorised as an 
anxiolytic-sensitive biomarker (McNaughton, 2017; Shadli et al., 2015), the results from my 
GAD and MDD patients and treatment resistant patients suggests that extremely high GCSR 
may actually represent a process that is anxiolytic-insensitive. These findings are challenging 
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to interpret. One possibility, as outlined earlier, is that chronic anxiety causes neural changes 
(e.g., release of cortisol; Korte, 2001; Mantella et al., 2008) that result in syndromal 
comorbidities (i.e., the patient develops other hyper-reactive neural systems; McNaughton & 
Corr, 2016). Over time, the chronic anxiety may cause changes in a neural system that is 
related to the GCSR, but unresponsive to common anxiolytics and antidepressants. In a recent 
study Glue et al. (2019), found ketamine, a N-methyl-D-aspartate (NMDA) receptor 
antagonist, to be effective in patients with treatment resistant GAD and SAD. Further, 
ketamine was found to reduce right frontal theta activity that was not affected by midazolam 
(i.e., benzodiazepine). While it is possible that the lack of midazolam effect could explain the 
treatment resistance, the authors concluded that ketamine affects a different right frontal 
system, which is also mediated by theta rhythmicity. Further research is required though to 
investigate the relationship between treatment resistant patients and GCSR.  
Figure 4.2. Frequency variation of goal-conflict specific rhythmicity at F8 averaged from five 
treatment resistant patients in block 2. The treatment resistant group appears to have a 
strong positive peak between 4-12Hz, similar to the High STAI-T group from the SJS 
analysis. The amplitude of GCSR from the treatment resistant group is stronger than GCSR 
from patients with comorbid GAD and MDD or High STAI-T scores.  Abbreviations: con, 
controls from the community analysis; gad + mdd, patients with comorbid generalised 
anxiety disorder and major depressive disorder; high sjs, High STAI-T group from the SJS 
analysis; tra, treatment resistant patients.  
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 Patients diagnosed with SAD were found to have the strongest GCSR overall. 
Interestingly, patients in this group also reported the highest PID-DEP scores. These findings 
suggest that GCSR may measure a neural process underlying both anxiety and depression 
(i.e., general susceptibility to negative affect). Single-dose drug experiments have shown 
GCSR to be reduced by anxiolytic drugs, not anti-depressants though (McNaughton et al., 
2013; Shadli et al., 2015). Goal-conflict specific rhythmicity studies to date indicate that 
GCSR is likely more related to anxiety than depression; however, future research should 
compare GCSR between patients diagnosed with pure GAD, pure MDD, and comorbid GAD 
and MDD to clarify this relationship.  
 
4.6 Strengths and limitations 
A key strength of this thesis was that I looked at GCSR across a broader frequency 
range than previous GCSR studies; 2-13Hz rather than the previous 5-11Hz. The purpose of 
investigating GCSR across this wider frequency band was to see whether important variations 
in GCSR exist beyond the conventional 4-12Hz range. As shown in Figure 4.1, I found 
significant variations in GCSR between DSM-IV-TR (APA, 2000) anxiety disorder 
diagnosed patients and controls between 2-5Hz in blocks 2 and 3. Patients diagnosed with 
GAD and MDD were also found to have strong GCSR, different from patients with other 
anxiety disorder diagnoses at 3Hz (see Figure 3.4). The broader frequency range revealed 
patterns at lower frequencies that would have been previously been missed. 
A limitation with this thesis was the uneven number of males to females across the 
different subgroups. This imbalance was largely due to difficulties in recruiting male 
participants. While it is unclear how gender might have affected my results, functional and 
structural neural differences are reported to exist between males and females (Ritchie et al., 
2018). Although there are some inconsistencies, EEG studies have shown that females 
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generally produce higher amplitude of brain activity across different frequency bands 
compared to males (Duregger et al., 2007; Li, Huang, Constable, & Sinha, 2006; Marques et 
al., 2016). For example, Kober and Neuper (2011) investigated the difference in frontal-
midline theta between males and females during a virtual navigation task. They found 
females to have stronger frontal-midline theta (6-10Hz) during navigation compared to 
males; despite no significant gender difference in task performance. Although frontal-midline 
theta was not measured in my analyses (i.e., frontal-midline theta is increased by anxiolytic 
drugs, while the right-frontal GCSR measured in this thesis is reduced by them; Mitchell et 
al., 2008), the findings from Kober and Neuper's (2011) study suggests that cortical theta 
activity is affected by gender. The prevalence of anxiety disorders is also different between 
genders, with females reporting a much higher 12-month and lifetime prevalence than males 
(Hink et al., 2013; McLean, Asnaani, Litz, & Hofmann, 2011). Considering the gender 
differences reported in the literature, future research involving a larger sample of male 
participants should investigate whether there are any significant differences in GCSR 
between males and females.  
Another limitation in this thesis was the small and uneven groups of participants 
across my analyses. For example, the pooled other anxiety disorder diagnosis group only had 
10 patients compared to my GAD group, which had 16 patients. As noted in Chapter 2, 
patients in my sample were clinically diagnosed for the first time during recruitment. For this 
reason, I was unable to recruit patients with specific DSM anxiety disorder diagnoses. Small 
sample sizes are problematic because they contribute to low statistical power (Larson & 
Carbine, 2017). Button et al. (2013) suggested that small sample sizes commonly result in 
higher variability, low reliability, and exaggerated significant effects. The pattern of GCSR 
observed across my analyses could have been due to a type 1 error. To investigate whether 
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my findings are from true effects, a replication is needed with a larger sample SJS and 
community recruited participants.  
Lastly – as seen in Figures 3.1 and 4.1 – GCSR varies across blocks. Due to this 
within-task instability, GCSR is considered to have low test-retest reliability (McNaughton, 
2014). A recent study by Shadli, McIntosh, and McNaughton (2019) also found that 
measuring resting EEG before the SST almost completely erased GCSR. Although my 
findings suggest that GCSR elicited by the SST is a clinically relevant measure on a group 
level, it is too unreliable to be used on an individual level for diagnosis. Therefore, a more 
controlled and robust method of eliciting GCSR is needed in the future for GCSR to translate 
into the clinic. 
4.7 Future research 
While several challenges have been identified throughout this thesis, the next key step 
with GCSR research would be to replicate the fourth analysis with a larger patient sample and 
to look at the effects of different anxiolytic drugs on GCSR in DSM-IV-TR (APA, 2000) 
anxiety disorder diagnosed patients.  
In my fourth analysis, patients were separated based on their primary diagnosis of 
GAD, GAD and MDD, SAD, and pooled others because this grouping yielded the most 
balanced sized groups. The groups were small though, so it is unclear whether my findings 
were due to true effects. Recruitment of more patients would allow GCSR comparisons 
between patients with other DSM-IV-TR (APA, 2000) anxiety disorder diagnoses as well. In 
particular, it would be interesting to test the relationship between GCSR and the number of 
comorbid diagnoses. Given that chronic anxiety leads to the emergence of comorbid 
syndromes and symptoms (McNaughton & Corr, 2016), I would expect that patients 
experiencing multiple disorders would show increased GCSR compared to patients diagnosed 
with one disorder. 
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In my second analysis, I found DSM-IV-TR (APA, 2000) anxiety disorder diagnosed 
patients to show increased GCSR at lower frequencies compared to students in my first 
analysis (see Figure 4.1). These findings suggest that DSM-IV-TR (APA, 2000) anxiety 
disorder diagnosed patients may produce different patterns of GCSR to students without 
clinical diagnosis (see Sections 4.3). Researchers to date have only investigated the effects of 
anxiolytics in healthy students. Examining the effects of anxiolytic drugs on GCSR in 
patients with DSM-IV-TR anxiety disorder would clarify the relationship between clinical 
anxiety and GCSR.  
4.8 Conclusion 
The present thesis provides evidence that goal-conflict specific rhythmicity is a 
clinically relevant measure for an anxiety syndrome. This was found through comparing 
GCSR recorded from the SST between DSM-IV-TR anxiety disorder diagnosed patients and 
age-matched controls. While previous research has demonstrated GCSR as being sensitive to 
different types of anxiolytic drugs (McNaughton et al., 2013; Shadli et al., 2015) and 
positively correlated to measures of trait anxiety and neuroticism (Neo & McNaughton, 
2011), this is the first study to show that GCSR is stronger in clinically diagnosed DSM-IV-
TR (APA, 2000) anxiety disorder patients than age-matched controls. The present study also 
compared GCSR between patients with different DSM-IV-TR anxiety disorder diagnoses. 
Despite my initial prediction that no DSM-IV-TR disorder would be linked to high GCSR, I 
found patients with comorbid GAD and MDD to have exceptionally strong GCSR in block 2. 
These findings provide preliminary evidence that the ‘anxiety disorders’ in the DSM-IV-TR 
may be more accurate than initially expected. My results also suggests that GCSR is 
extremely high in patients with chronic anxiety. While further research with a larger sample 
of clinical patients is required to support my findings, this thesis has contributed to the 
ongoing development of a clinically translatable human biomarker for an anxiety syndrome. 
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Once clinically translated, GCSR has the potential to predict treatment outcomes with higher 
accuracy than the current diagnostic tools in psychiatry and guide the development of other 
biomarkers for mental disorders. The development of biomarkers for psychiatry would 
























ANXIETY BIOMARKER 80 
References 
Adamec, R. E., & McKay, D. (1993). Amygdala kindling, anxiety, and corticotrophin 
releasing factor (CRF). Physiology & Behavior, 54(3), 423–431.  
Adamec, R. E., & Young, B. (2000). Neuroplasticity in specific limbic system circuits may 
mediate specific kindling induced changes in animal affect—implications for 
understanding anxiety associated with epilepsy. Neuroscience & Biobehavioral 
Reviews, 24(7), 705–723.  
Albaugh, M. D., Nguyen, T. V., Ducharme, S., Collins, D. L., Botteron, K. N., D’Alberto, N., 
. . . Hudziak, J. J. (2017). Age-related volumetric change of limbic structures and 
subclinical anxious/depressed symptomatology in typically developing children and 
adolescents. Biological psychology, 124, 133–140. 
doi:https://doi.org/10.1016/j.biopsycho.2017.02.002 
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental 
Disorders (4th ed.). Washington, DC. 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (4
th
 ed., text rev.). Washington, DC: Author.  
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (DSM-5®): American Psychiatric Pub. 
Aron, A. R., & Poldrack, R. A. (2006). Cortical and subcortical contributions to stop signal 
response inhibition: role of the subthalamic nucleus. Journal of Neuroscience, 26(9), 
2424–2433.  
Bados, A., Gómez-Benito, J., & Balaguer, G. (2010). The State-Trait Anxiety Inventory, 
Trait Version: Does It Really Measure Anxiety? Journal of Personality Assessment, 
92(6), 560–567. doi:10.1080/00223891.2010.513295 
ANXIETY BIOMARKER 81 
Baldwin, D. (2008). Room for Improvement in the Pharmacological Treatment of Anxiety 
Disorders. Current Pharmaceutical Design, 14(33), 3482–3491. 
doi:10.2174/138161208786848810 
Ballenger, J. C. (1999). Current treatments of the anxiety disorders in adults. Biological 
Psychiatry, 46(11), 1579–1594. doi:https://doi.org/10.1016/S0006-3223(99)00220-6 
Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., & Moller, H. J. 
(2012). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-
compulsive disorder and posttraumatic stress disorder in primary care. Int J 
Psychiatry Clin Pract, 16(2), 77–84. doi:10.3109/13651501.2012.667114 
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000). Cognitive-behavioral 
therapy, imipramine, or their combination for panic disorder: A randomized 
controlled trial. JAMA, 283(19), 2529–2536.  
Baxter, A., Vos, T., Scott, K., Ferrari, A., & Whiteford, H. (2014). The global burden of 
anxiety disorders in 2010. Psychological Medicine, 44(11), 2363–2374.  
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring 
clinical anxiety: psychometric properties. Journal of consulting and clinical 
psychology, 56(6), 893.  
Benchenane, K., Tiesinga, P. H., & Battaglia, F. P. (2011). Oscillations in the prefrontal 
cortex: a gateway to memory and attention. Current Opinion in Neurobiology, 21(3), 
475–485.  
Berlucchi, G. (2009). Neuropsychology: Theoretical Basis. In L. R. Squire (Ed.), 
Encyclopedia of Neuroscience (pp. 1001–1006). Oxford: Academic Press. 
Bieling, P. J., Antony, M. M., & Swinson, R. P. (1998). The State-Trait Anxiety Inventory, 
Trait version: structure and content re-examined. Behaviour research and therapy, 
36(7), 777–788.  
ANXIETY BIOMARKER 82 
Blanchard, D. C., & Blanchard, R. J. (1988). Ethoexperimental approaches to the biology of 
emotion. Annu Rev Psychol, 39(1), 43–68. doi:10.1146/annurev.ps.39.020188.000355 
Blanchard, D. C., Blanchard, R. J., Tom, P., & Rodgers, R. J. (1990). Diazepam changes risk 
assessment in an anxiety/defense test battery. Psychopharmacology (Berl), 101(4), 
511–518. doi:10.1007/bf02244230 
Blanchard, R. J., & Blanchard, D. C. (1989). Antipredator defensive behaviors in a visible 
burrow system. J Comp Psychol, 103(1), 70–82.  
Blanchard, R. J., Blanchard, D. C., Rodgers, J., & Weiss, S. M. (1990b). The characterization 
and modelling of antipredator defensive behavior. Neuroscience & Biobehavioral 
Reviews, 14(4), 463–472.  
Blanchard, R. J., Griebel, G., Henrie, J. A., & Blanchard, D. C. (1997). Differentiation of 
anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. 
Neurosci Biobehav Rev, 21(6), 783–789.  
Blanchard, R. J., Yudko, E. B., Rodgers, R. J., & Blanchard, D. C. (1993). Defense system 
psychopharmacology: an ethological approach to the pharmacology of fear and 
anxiety. Behav Brain Res, 58(1–2), 155–165. doi:10.1016/0166-4328(93)90100-5 
Bleakley, S., & Davies, S. J. (2014). The pharmacological management of anxiety disorders. 
Progress in Neurology and Psychiatry, 18(6), 27–32.  
Breggin, P. R. (1964). The psychophysiology of anxiety: with a review of the literature 
concerning adrenaline. The Journal of Nervous and Mental Disease, 139(6), 558–568.  
Button, K. S., Ioannidis, J. P., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S., & 
Munafò, M. R. (2013). Power failure: why small sample size undermines the 
reliability of neuroscience. Nature Reviews Neuroscience, 14(5), 365.  
Bystritsky, A. (2006). Treatment-resistant anxiety disorders. Mol Psychiatry, 11(9), 805–814.  
ANXIETY BIOMARKER 83 
Bystritsky, A., Khalsa, S. S., Cameron, M. E., & Schiffman, J. (2013). Current diagnosis and 
treatment of anxiety disorders. PT, 38(1), 30–57.  
Carter, J. D., Farrow, M., Silberstein, R. B., Stough, C., Tucker, A., & Pipingas, A. (2003). 
Assessing inhibitory control: A revised approach to the stop signal task. Journal of 
Attention Disorders, 6(4), 153–161. doi:10.1177/108705470300600402 
Carver, C. S., & White, T. L. (1994). Behavioral inhibition, behavioral activation, and 
affective responses to impending reward and punishment: The BIS/BAS Scales. 
Journal of Personality and Social Psychology, 67(2), 319–333. doi:10.1037/0022-
3514.67.2.319 
Cavanagh, J. F., Bismark, A. W., Frank, M. J., & Allen, J. J. B. (2019). Multiple 
Dissociations Between Comorbid Depression and Anxiety on Reward and 
Punishment Processing: Evidence From Computationally Informed EEG. 
Computational psychiatry (Cambridge, Mass.), 3, 1–17. doi:10.1162/cpsy_a_00024 
Centre for Disease Control. (2017). Chickenpox (varicella).  
Charney, D. S., Woods, S. W., Goodman, W. K., Rifkin, B., Kinch, M., Aiken, B., . . . 
Heninger, G. R. (1986). Drug treatment of panic disorder: The comparative efficacy 
of imipramine, alprazolam, and trazodone. The Journal of clinical psychiatry, 47(12), 
580–586.  
Cohen, H., Benjamin, J., Kaplan, Z., & Kotler, M. (2000). Administration of high-dose 
ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an 
animal model. European Neuropsychopharmacology, 10(6), 429–435. 
doi:https://doi.org/10.1016/S0924-977X(00)00105-X 
Coplan, J. D., Aaronson, C. J., Panthangi, V., & Kim, Y. (2015). Treating comorbid anxiety 
and depression: Psychosocial and pharmacological approaches. World journal of 
psychiatry, 5(4), 366–378. doi:10.5498/wjp.v5.i4.366 
ANXIETY BIOMARKER 84 
Corr, P. J. (2011). Anxiety: Splitting the phenomenological atom. Personality and Individual 
Differences, 50(7), 889–897. doi:http://dx.doi.org/10.1016/j.paid.2010.09.013 
Corr, P. J., DeYoung, C. G., & McNaughton, N. (2013). Motivation and Personality: A 
Neuropsychological Perspective. Social and Personality Psychology Compass, 7(3), 
158–175. doi:10.1111/spc3.12016 
Corr, P. J., & McNaughton, N. (2012). Neuroscience and approach/avoidance personality 
traits: A two stage (valuation–motivation) approach. Neuroscience & Biobehavioral 
Reviews, 36(10), 2339–2354. doi:https://doi.org/10.1016/j.neubiorev.2012.09.013 
Corr, P. J., & Perkins, A. M. (2006). The role of theory in the psychophysiology of 
personality: From Ivan Pavlov to Jeffrey Gray. International Journal of 
Psychophysiology, 62(3), 367–376.  
Cuthbert, B. N., & Insel, T. R. (2013). Toward the future of psychiatric diagnosis: the seven 
pillars of RDoC. BMC Medicine, 11, 126–126. doi:10.1186/1741-7015-11-126 
Darwin, C., & Prodger, P. (1998). The expression of the emotions in man and animals: 
Oxford University Press, USA. 
Davidson, J. R., DuPont, R. L., Hedges, D., & Haskins, J. T. (1999). Efficacy, safety, and 
tolerability of venlafaxine extended release and buspirone in outpatients with 
generalized anxiety disorder. The Journal of clinical psychiatry.  
Davidson, R. J. (2002). Anxiety and affective style: role of prefrontal cortex and amygdala. 
Biological Psychiatry, 51(1), 68–80.  
Del-Ben, C. M., & Graeff, F. G. (2009). Panic disorder: is the PAG involved? Neural 
plasticity, 2009, 108135–108135. doi:10.1155/2009/108135 
Duregger, C., Bauer, H., Cunnington, R., Lindinger, G., Deecke, L., Lang, W., . . . Walla, P. 
(2007). EEG evidence of gender differences in a motor related CNV study. Journal of 
Neural Transmission, 114(3), 359–366. doi:10.1007/s00702-006-0568-5 
ANXIETY BIOMARKER 85 
Durham, R. C., Murphy, T., Allan, T., Richard, K., Treliving, L. R., & Fenton, G. W. (1994). 
Cognitive Therapy, Analytic Psychotherapy and Anxiety Management Training for 
Generalised Anxiety Disorder. British Journal of Psychiatry, 165(3), 315–323. 
doi:10.1192/bjp.165.3.315 
Eysenck, H. J., & Eysenck, S. B. G. (1991). Manual of the Eysenck personality scales (EPS 
adult) : comprising the EPQ-revised (EPQ-R) (including addiction and criminality 
scales), EPQ-R short scale, impulsiveness (IVE) questionnaire (implsiveness/ 
venturesomeness/empathy). London [etc.]: Hodder & Stoughton. 
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy-Byrne, P. P. (2012). 
Pharmacological treatment of anxiety disorders: Current treatments and future 
directions. Journal of anxiety disorders, 26(8), 833–843. 
doi:10.1016/j.janxdis.2012.07.009 
Fell, D., Derbyshire, D., Maile, C., Larsson, I.-M., Ellis, R., Achola, K., & Smith, G. (1985). 
Measurement of plasma catecholamine concentrations: an assessment of anxiety. 
British Journal of Anaesthesia, 57(8), 770–774.  
Fernández, A., Rubio-Valera, M., Bellón, J. A., Pinto-Meza, A., Luciano, J. V., Mendive, J. 
M., . . . Serrano-Blanco, A. (2012). Recognition of anxiety disorders by the general 
practitioner: results from the DASMAP Study. General Hospital Psychiatry, 34(3), 
227–233. doi:https://doi.org/10.1016/j.genhosppsych.2012.01.012 
Fisher, P. L., & Durham, R. C. (1999). Recovery rates in generalized anxiety disorder 
following psychological therapy: an analysis of clinically significant change in the 
STAI-T across outcome studies since 1990. Psychological Medicine, 29(6), 1425–
1434.  
ANXIETY BIOMARKER 86 
Fung, B., Qi, S., Hassabis, D., Daw, N., & Mobbs, D. (2019). Slow escape decisions are 
swayed by trait anxiety. Nature Human Behaviour, 3. doi:10.1038/s41562-019-0595-
5 
Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., . . . Medlicott, 
N. J. (2019). Effects of ketamine in patients with treatment-refractory generalized 
anxiety and social anxiety disorders: Exploratory double-blind psychoactive-
controlled replication study. Journal of Psychopharmacology, 34(3), 267–272. 
doi:10.1177/0269881119874457 
Goldberg, D. P., & Huxley, P. (1992). Common mental disorders: a bio-social model: 
Tavistock/Routledge. 
Goldstein-Piekarski, A. N., Williams, L. M., & Humphreys, K. (2016). A trans-diagnostic 
review of anxiety disorder comorbidity and the impact of multiple exclusion criteria 
on studying clinical outcomes in anxiety disorders. Translational psychiatry, 6(6), 
e847. doi:10.1038/tp.2016.108 
Gorman, J. M. (1996). Comorbid depression and anxiety spectrum disorders. Depression and 
anxiety, 4(4), 160–168.  
Graeff, F. (1991). Neurotransmitters in the dorsal periaqueductal grey and animal models of 
panic anxiety New concepts in anxiety (pp. 288–312): Springer. 
Graeff, F. G. (1994). Neuroanatomy and neurotransmitter regulation of defensive behaviors 
and related emotions in mammals. Brazilian journal of medical and biological 
research= Revista brasileira de pesquisas medicas e biologicas, 27(4), 811–829.  
Graeff, F. G., & Zangrossi, H., Jr. (2010). The dual role of serotonin in defense and the mode 
of action of antidepressants on generalized anxiety and panic disorders. Cent Nerv 
Syst Agents Med Chem, 10(3), 207–217.  
ANXIETY BIOMARKER 87 
Gray, J. A., & McNaughton, N. (2000). The neuropsychology of anxiety an enquiry into the 
functions of the septo-hippocampal system (2nd ed. ed.). Oxford: Oxford University 
Press. 
Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. 
R., . . . Fyer, A. J. (1999). The economic burden of anxiety disorders in the 1990s. The 
Journal of clinical psychiatry.  
Grös, D. F., Antony, M. M., Simms, L. J., & McCabe, R. E. (2007). Psychometric properties 
of the State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA): 
comparison to the State-Trait Anxiety Inventory (STAI). Psychological assessment, 
19(4), 369.  
Hall, J., O'Carroll, R. E., & Frith, C. D. (2010). 7 - Neuropsychology. In E. C. Johnstone, D. 
C. Owens, S. M. Lawrie, A. M. McIntosh, & M. Sharpe (Eds.), Companion to 
Psychiatric Studies (Eighth Edition) (pp. 121–140). St. Louis: Churchill Livingstone. 
Hammen, C. (2005). Stress and depression. Annu. Rev. Clin. Psychol., 1, 293–319.  
Hannon, J., & Hoyer, D. (2008). Molecular biology of 5-HT receptors. Behavioural Brain 
Research, 195(1), 198–213.  
Harper, J., Malone, S. M., & Iacono, W. G. (2017). Theta- and delta-band EEG network 
dynamics during a novelty oddball task. Psychophysiology, 54(11), 1590–1605. 
doi:10.1111/psyp.12906 
Harris, J. C. (1989). Experimental Animal Modeling of Depression and Anxiety. Psychiatric 
Clinics of North America, 12(4), 815–836. doi:https://doi.org/10.1016/S0193-
953X(18)30399-X 
Hergueta, T., Baker, R., & Dunbar, G. C. (1998). The Mini-International Neuropsychiatric 
Interview (MINI): the development and validation of a structured diagnostic 
psychiatric interview for DSM-IV and ICD-10. J clin psychiatry, 59(Suppl 20), 2233.  
ANXIETY BIOMARKER 88 
Hink, L. K., Rhee, S. H., Corley, R. P., Cosgrove, V. E., Hewitt, J. K., Schulz-Heik, R. J., . . . 
Waldman, I. D. (2013). Personality Dimensions as Common and Broadband-Specific 
Features for Internalizing and Externalizing Disorders. Journal of Abnormal Child 
Psychology, 41(6), 939–957. doi:10.1007/s10802-013-9730-3 
Hirschfeld, R. M. A. (2001). The Comorbidity of Major Depression and Anxiety Disorders: 
Recognition and Management in Primary Care. Primary Care Companion to The 
Journal of Clinical Psychiatry, 3(6), 244–254.  
Huh, J., Goebert, D., Takeshita, J., Lu, B. Y., & Kang, M. (2011). Treatment of Generalized 
Anxiety Disorder: A Comprehensive Review of the Literature for 
Psychopharmacologic Alternatives to Newer Antidepressants and Benzodiazepines. 
The Primary Care Companion to CNS Disorders, 13(2), PCC.08r00709. 
doi:10.4088/PCC.08r00709blu 
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., . . . Wang, P. (2010). 
Research domain criteria (RDoC): toward a new classification framework for research 
on mental disorders: Am Psychiatric Assoc. 
Institute for Health Metrics and Evaluation. (2013). GBD Compare. Retrieved from 
http://vizhub.healthdata.org/gbd-compare  
Julian, L. J. (2011). Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck 
Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety 
(HADS-A). Arthritis care & research, 63 Suppl 11(0 11), S467–S472. 
doi:10.1002/acr.20561 
Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., . . . 
Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric 
disorders in the United States: results from the National Comorbidity Survey. 
Archives of General Psychiatry, 51(1), 8–19.  
ANXIETY BIOMARKER 89 
Kober, S. E., & Neuper, C. (2011). Sex differences in human EEG theta oscillations during 
spatial navigation in virtual reality. International Journal of Psychophysiology, 79(3), 
347–355. doi:https://doi.org/10.1016/j.ijpsycho.2010.12.002 
Korte, S. (2001). Corticosteroids in relation to fear, anxiety and psychopathology. 
Neuroscience & Biobehavioral Reviews, 25(2), 117–142.  
Kroenke, K., Spitzer, R. L., Williams, J. W., Monahan, P. O., & Löwe, B. (2007). Anxiety 
disorders in primary care: Prevalence, impairment, comorbidity, and detection. Annals 
of Internal Medicine, 146(5), 317–325. doi:10.7326/0003-4819-146-5-200703060-
00004 
Kupfer, D. J. (2015). Anxiety and DSM-5. Dialogues in clinical neuroscience, 17(3), 245–
246.  
Lamberg, T. S., Kivistö, K. T., & Neuvonen, P. J. (1998). Effects of verapamil and diltiazem 
on the pharmacokinetics and pharmacodynamics of buspirone. Clinical 
Pharmacology & Therapeutics, 63(6), 640–645.  
Langerhans, R. B. (2007). Evolutionary consequences of predation: avoidance, escape, 
reproduction, and diversification Predation in organisms (pp. 177–220): Springer. 
Larson, M. J., & Carbine, K. A. (2017). Sample size calculations in human electrophysiology 
(EEG and ERP) studies: A systematic review and recommendations for increased 
rigor. International Journal of Psychophysiology, 111, 33–41. 
doi:https://doi.org/10.1016/j.ijpsycho.2016.06.015 
Lauria-Horner, B. A., & Pohl, R. B. (2003). Pregabalin: a new anxiolytic. Expert opinion on 
investigational drugs, 12(4), 663–672.  
Lecrubier, Y., Sheehan, D. V., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., . . . 
Dunbar, G. C. (1997). The Mini International Neuropsychiatric Interview (MINI). A 
ANXIETY BIOMARKER 90 
short diagnostic structured interview: reliability and validity according to the CIDI. 
European psychiatry, 12(5), 224–231.  
Ledoux, J. E., & Pine, D. S. (2016). Using Neuroscience to Help Understand Fear and 
Anxiety: A Two-System Framework. The American Journal of Psychiatry, 173(11), 
1083. doi:10.1176/appi.ajp.2016.16030353 
Lépine, J. P., & Briley, M. (2011). The increasing burden of depression. Neuropsychiatric 
Disease and Treatment, 7(Suppl 1), 3.  
Lesch, K.-P. (2011). When the Serotonin Transporter Gene Meets Adversity: The 
Contribution of Animal Models to Understanding Epigenetic Mechanisms in 
Affective Disorders and Resilience. In J. J. Hagan (Ed.), Molecular and Functional 
Models in Neuropsychiatry (pp. 251–280). Berlin, Heidelberg: Springer Berlin 
Heidelberg. 
Leung, L. S., & Ma, J. (2017). Behavioral Hyperactivity and Psychiatric Symptoms Induced 
by Seizures. Reference Module in Neuroscience and Biobehavioral Psychology: 
Elsevier. 
Li, C. S. R., Huang, C., Constable, R. T., & Sinha, R. (2006). Gender differences in the 
neural correlates of response inhibition during a stop signal task. NeuroImage, 32(4), 
1918–1929. doi:https://doi.org/10.1016/j.neuroimage.2006.05.017 
Lipszyc, J., & Schachar, R. (2010). Inhibitory control and psychopathology: A meta-analysis 
of studies using the stop signal task. Journal of the International Neuropsychological 
Society, 16(6), 1064–1076. doi:10.1017/S1355617710000895 
Lissek, S., Levenson, J., Biggs, A. L., Johnson, L. L., Ameli, R., Pine, D. S., & Grillon, C. 
(2008). Elevated Fear Conditioning to Socially Relevant Unconditioned Stimuli in 
Social Anxiety Disorder. The American Journal of Psychiatry, 165(1), 124–132. 
doi:10.1176/appi.ajp.2007.06091513 
ANXIETY BIOMARKER 91 
Logan, G. D., & Cowan, W. B. (1984). On the ability to inhibit thought and action: A theory 
of an act of control. Psychological review, 91(3), 295–327. doi:10.1037/0033-
295X.91.3.295 
Mantella, R. C., Butters, M. A., Amico, J. A., Mazumdar, S., Rollman, B. L., Begley, A. E., . 
. . Lenze, E. J. (2008). Salivary cortisol is associated with diagnosis and severity of 
late-life generalized anxiety disorder. Psychoneuroendocrinology, 33(6), 773–781.  
Marques, A. A., Bevilaqua, M. C. d. N., da Fonseca, A. M. P., Nardi, A. E., Thuret, S., & 
Dias, G. P. (2016). Gender Differences in the Neurobiology of Anxiety: Focus on 
Adult Hippocampal Neurogenesis. Neural plasticity, 2016, 5026713-5026713. 
doi:10.1155/2016/5026713 
Martin, I. L., & Candy, J. M. (1980). Facilitation of specific benzodiazepine binding in rat 
brain membrane fragments by a number of anions. Neuropharmacology, 19(2), 175–
179. doi:https://doi.org/10.1016/0028-3908(80)90135-5 
Martin, J. L. R., Sainz-Pardo, M., Furukawa, T. A., Martin-Sanchez, E., Seoane, T., & Galan, 
C. (2007). Benzodiazepines in generalized anxiety disorder: heterogeneity of 
outcomes based on a systematic review and meta-analysis of clinical trials. Journal of 
Psychopharmacology, 21(7), 774–782.  
Mayr, E. (1974). Teleological and teleonomic, a new analysis Methodological and historical 
essays in the natural and social sciences (pp. 91–117): Springer. 
McIntosh, J. (2017). Is Goal Conflict Speciic Rhythmicity a Biomarker for a Type of Clinical 
Anxiety? (Masters of Science), University of Otago, Dunedin, New Zealand. 
Retrieved from 
https://ourarchive.otago.ac.nz/bitstream/handle/10523/7813/McIntoshJuliaF2017MSc.
pdf?sequence=1&isAllowed=y   
ANXIETY BIOMARKER 92 
McLean, C. P., Asnaani, A., Litz, B. T., & Hofmann, S. G. (2011). Gender differences in 
anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. 
Journal of psychiatric research, 45(8), 1027–1035. 
doi:10.1016/j.jpsychires.2011.03.006 
McNaughton, N. (1989). Biology and emotion: Cambridge University Press. 
McNaughton, N. (2014). Development of a theoretically-derived human anxiety syndrome 
biomarker. Translational Neuroscience, 5(2), 137–146. doi:10.2478/s13380-014-
0220-z 
McNaughton, N. (2017). What do you mean ‘anxiety’? Developing the first anxiety 
syndrome biomarker. Journal of the Royal Society of New Zealand, 1–14. 
doi:10.1080/03036758.2017.1358184 
McNaughton, N., & Coop, C. F. (1991). Neurochemically dissimilar anxiolytic drugs have 
common effects on hippocampal rhythmic slow activity. Neuropharmacology, 30(8), 
855–863. doi:https://doi.org/10.1016/0028-3908(91)90119-V 
McNaughton, N., & Corr, P. J. (2004). A two-dimensional neuropsychology of defense: 
fear/anxiety and defensive distance. Neuroscience & Biobehavioral Reviews, 28(3), 
285–305. doi:https://doi.org/10.1016/j.neubiorev.2004.03.005 
McNaughton, N., & Corr, P. J. (2008). The neuropsychology of fear and anxiety: A 
foundation for reinforcement sensitivity theory. The reinforcement sensitivity theory 
of personality, 44–94.  
McNaughton, N., & Corr, P. J. (2014). Approach, avoidance, and their conflict: the problem 
of anchoring.  
McNaughton, N., & Corr, P. J. (2016). Mechanisms of comorbidity, continuity, and 
discontinuity in anxiety-related disorders. Development and psychopathology, 
28(4pt1), 1053–1069.  
ANXIETY BIOMARKER 93 
McNaughton, N., DeYoung, C. G., & Corr, P. J. (2015). Approach/Avoidance. Neuroimaging 
personality, social cognition and character: Traits and mental states in the brain. 
London: Elsevier.  
McNaughton, N., Kocsis, B., & Hajós, M. (2007). Elicited hippocampal theta rhythm: a 
screen for anxiolytic and procognitive drugs through changes in hippocampal 
function? Behavioural pharmacology, 18(5–6), 329. 
doi:10.1097/FBP.0b013e3282ee82e3 
McNaughton, N., Ruan, M., & Woodnorth, M. A. (2006). Restoring theta‐like rhythmicity in 
rats restores initial learning in the Morris water maze. Hippocampus, 16(12), 1102–
1110.  
McNaughton, N., Swart, C., Neo, P., Bates, V., & Glue, P. (2013). Anti-anxiety drugs reduce 
conflict-specific “theta”—A possible human anxiety-specific biomarker. Journal of 
Affective Disorders, 148(1), 104–111. doi:https://doi.org/10.1016/j.jad.2012.11.057 
McNaughton, N., & Zangrossi, H. (2008). .1 Theoretical approaches to the modeling of 
anxiety in animals. Handbook of behavioral neuroscience, 17, 11–27.  
Meduri, G. U., Mauldin, G. L., Wunderink, R. G., Leeper, K. V., Jones, C. B., Tolley, E., & 
Mayhall, G. (1994). Causes of Fever and Pulmonary Densities in Patients with 
Clinical Manifestations of Ventilator-Associated Pneumonia. Chest, 106(1), 221–235. 
doi:https://doi.org/10.1378/chest.106.1.221 
Mendlowicz, M. V., & Stein, M. B. (2000). Quality of Life in Individuals With Anxiety 
Disorders. American Journal of Psychiatry, 157(5), 669–682. 
doi:10.1176/appi.ajp.157.5.669 
Mineka, S., and, D. W., & Clark, L. A. (1998). Comorbidity of anxiety and unipolar mood 
disorders. Annual Review of Psychology, 49(1), 377–412. 
doi:10.1146/annurev.psych.49.1.377 
ANXIETY BIOMARKER 94 
Ministry of Health. (2017, 11th June 2018). Annual Uppdate of Key Results 2016/17: New 
Zealand Health Survey. Retrieved from https://minhealthnz.shinyapps.io/nz-health-
survey-2016-17-annual-update 
Mitchell, D. J., McNaughton, N., Flanagan, D., & Kirk, I. J. (2008). Frontal-midline theta 
from the perspective of hippocampal “theta”. Progress in neurobiology, 86(3), 156–
185.  
Mitchell, T. R., & Mickel, A. E. (1999). The meaning of money: An individual-difference 
perspective. Academy of management review, 24(3), 568–578.  
Moers-Hornikx, V. M. P., Vles, J. S. H., Lim, L. W., Ayyildiz, M., Kaplan, S., Gavilanes, A. 
W. D., . . . Temel, Y. (2011). Periaqueductal Grey Stimulation Induced Panic-Like 
Behaviour Is Accompanied by Deactivation of the Deep Cerebellar Nuclei. 
Cerebellum (London, England), 10(1), 61–69. doi:10.1007/s12311-010-0228-z 
Moffitt, T. E., Harrington, H., & Caspi, A. (2007). Depression and generalized anxiety 
disorder: Cumulative and sequential comorbidity in a birth cohort followed 
prospectively to age 32 years. Archives of General Psychiatry, 64(6), 651–660. 
doi:10.1001/archpsyc.64.6.651 
Moffitt, T. E., Harrington, H., Caspi, A., Kim-Cohen, J., Goldberg, D., Gregory,A. M., & 
Poulton, R. (2007). Depression and Generalized Anxiety Disorder: Cumulative and 
Swquential Comorbidity in a Birth Cohort Followed Prospectively to Age 32 Years. 
Archives of General Psychiatry, 64(6), 651 - 660. doi:10.1001/archpsyc.64.6.651 
Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in 
the rat. Journal of neuroscience methods, 11(1), 47–60.  
Neo, P., & McNaughton, N. (2011). Frontal theta power linked to neuroticism and avoidance. 
Cognitive, Affective, & Behavioral Neuroscience, 11(3), 396–403. 
doi:10.3758/s13415-011-0038-x 
ANXIETY BIOMARKER 95 
Neo, P., Thurlow, J. K., & McNaughton, N. (2011). Stopping, goal-conflict, trait anxiety and 
frontal rhythmic power in the stop-signal task. Cognitive, Affective, & Behavioral 
Neuroscience, 11(4), 485–493.  
Nesse, R. M. (2000). Is depression an adaptation? Archives of General Psychiatry, 57(1), 14–
20.  
Newton, R. E., Marunycz, J. D., Alderdice, M. T., & Napoliello, M. J. (1986). Review of the 
side-effect profile of buspirone. The American Journal of Medicine, 80(3), 17–21. 
doi:10.1016/0002-9343(86)90327-X 
Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. 
D., . . . Yu, V. L. (2001). Guidelines for the management of adults with community-
acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and 
prevention. Am J Respir Crit Care Med, 163(7), 1730–1754. 
doi:10.1164/ajrccm.163.7.at1010 
Oakley-Browne, M., Wells, J. E., & Scott, K. M. (2006). Te Rau Hinengaro: The New 
Zealand Mental Health Survey: Summary: Ministry of Health. 
Oei, T. P., Evans, L., & Crook, G. M. (1990). Utility and validity of the STAI with anxiety 
disorder patients. British Journal of Clinical Psychology, 29(4), 429–432.  
Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007). Quality of life in the anxiety disorders: A 
meta-analytic review. Clinical Psychology Review, 27(5), 572–581. 
doi:https://doi.org/10.1016/j.cpr.2007.01.015 
Ormel, J., Jeronimus, B. F., Kotov, R., Riese, H., Bos, E. H., Hankin, B., . . . Oldehinkel, A. 
J. (2013). Neuroticism and common mental disorders: meaning and utility of a 
complex relationship. Clinical Psychology Review, 33(5), 686–697. 
doi:10.1016/j.cpr.2013.04.003 
ANXIETY BIOMARKER 96 
Ormel, J., Petukhova, M., Chatterji, S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., . 
. . Kessler, R. C. (2008). Disability and treatment of specific mental and physical 
disorders across the world. Br J Psychiatry, 192(5), 368–375. 
doi:10.1192/bjp.bp.107.039107 
Ormel, J., VonKorff, M., Ustun, T., Pini, S., Korten, A., & Oldehinkel, T. (1994). Common 
mental disorders and disability across cultures: Results from the who collaborative 
study on psychological problems in general health care. JAMA, 272(22), 1741–1748. 
doi:10.1001/jama.1994.03520220035028 
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., . . . 
Davidson, J. R. (2003). Pregabalin in generalized anxiety disorder: a placebo-
controlled trial. American Journal of Psychiatry, 160(3), 533–540.  
Panksepp, J., & Watt, D. (2011). Why Does Depression Hurt? Ancestral Primary-Process 
Separation-Distress (PANIC/GRIEF) and Diminished Brain Reward (SEEKING) 
Processes in the Genesis of Depressive Affect. Psychiatry: Interpersonal and 
Biological Processes, 74(1), 5–13. doi:10.1521/psyc.2011.74.1.5 
Parks, E. T., & Marek, C. (2007). Managing the Patient With Psychological Problems. In S. 
J. Stefanac & S. P. Nesbit (Eds.), Treatment Planning in Dentistry (Second Edition) 
(pp. 367–389). Saint Louis: Mosby. 
Parvizi, J., & Kastner, S. (2018). Promises and limitations of human intracranial 
electroencephalography. Nature neuroscience, 21(4), 474–483. doi:10.1038/s41593-
018-0108-2 
Proudfit, G. H. (2015). The reward positivity: From basic research on reward to a biomarker 
for depression. Psychophysiology, 52(4), 449–459. doi:10.1111/psyp.12370 
Pyke, R. E., & Greenberg, H. S. (1986). Norepinephrine Challenges in Panic Patients. 
Journal of Clinical Psychopharmacology, 6(5), 279–285.  
ANXIETY BIOMARKER 97 
Reddy, A. G., & Narava, S. (2013). Artifact removal from EEG signals. International 
Journal of Computer Applications, 77(13).  
Ritchie, S. J., Cox, S. R., Shen, X., Lombardo, M. V., Reus, L. M., Alloza, C., . . . Deary, I. J. 
(2018). Sex Differences in the Adult Human Brain: Evidence from 5216 UK Biobank 
Participants. Cerebral cortex (New York, N.Y. : 1991), 28(8), 2959–2975. 
doi:10.1093/cercor/bhy109 
Rosen, J. B., & Schulkin, J. (1998). From normal fear to pathological anxiety. Psychological 
review, 105(2), 325.  
Roy-Byrne, P. P., Stang, P., Wittchen, H. U., Ustun, B., Walters, E. E., & Kessler, R. C. 
(2000). Lifetime panic-depression comorbidity in the National Comorbidity Survey. 
Association with symptoms, impairment, course and help-seeking. Br J Psychiatry, 
176, 229–235.  
Sapolsky, R. M. (2016). Psychiatric distress in animals versus animal models of psychiatric 
distress. Nature neuroscience, 19(11), 1387–1389. doi:10.1038/nn.4397 
Shadli, S. M. (2019, 21st September). 
Shadli, S. M., Glue, P., McIntosh, J., & McNaughton, N. (2015). An improved human 
anxiety process biomarker: characterization of frequency band, personality and 
pharmacology. Translational psychiatry, 5(12), e699.  
Sheehan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1990). Is buspirone effective for 
panic disorder? Journal of Clinical Psychopharmacology.  
Siapas, A. G., Lubenov, E. V., & Wilson, M. A. (2005). Prefrontal phase locking to 
hippocampal theta oscillations. Neuron, 46(1), 141–151.  
Silva, C., & McNaughton, N. (2019). Are periaqueductal gray and dorsal raphe the 
foundation of appetitive and aversive control? A comprehensive review. Progress in 
neurobiology, 177, 33–72. doi:https://doi.org/10.1016/j.pneurobio.2019.02.001 
ANXIETY BIOMARKER 98 
Siok, C. J., Taylor, C. P., & Hajós, M. (2009). Anxiolytic profile of pregabalin on elicited 
hippocampal theta oscillation. Neuropharmacology, 56(2), 379–385.  
Spielberger, C. D., Gorsuch, R., Lushene, R. E., Vagg, P. R., & Jacobs, G. A. (1983). Manual 
for the State-Trait Anxiety Inventory (Form Y1 – Y2). Palo Alto: CA: Consulting 
Psychologists Press. 
Stiedl, O., Pappa, E., Konradsson-Geuken, A., & Ogren, S. O. (2015). The role of the 
serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional 
learning and memory. Front Pharmacol, 6, 162. doi:10.3389/fphar.2015.00162 
Sylvers, P., Lilienfeld, S. O., & LaPrairie, J. L. (2011). Differences between trait fear and 
trait anxiety: Implications for psychopathology. Clinical Psychology Review, 31(1), 
122–137. doi:https://doi.org/10.1016/j.cpr.2010.08.004 
Teplan, M. (2002). Fundamentals of EEG measurement. Measurement science review, 2(2), 
1–11.  
The Royal Australian and New Zealand College of Psychiatrists. (2016). The Economic Cost 
of Serious Mental Illness and Comorbidities in Australia and New Zealand. Retrieved 
from https://www.ranzcp.org/Files/Publications/RANZCP-Serious-Mental-
Illness.aspx 
Tunison, E., Sylvain, R., Sterr, J., Hiley, V., & Carlson, J. M. (2019). No Money, No 
Problem: Enhanced Reward Positivity in the Absence of Monetary Reward. Frontiers 
in Human Neuroscience, 13, 41–41. doi:10.3389/fnhum.2019.00041 
Van Veen, J., Van Vliet, I., DeRijk, R., Van Pelt, J., Mertens, B., & Zitman, F. (2008). 
Elevated alpha-amylase but not cortisol in generalized social anxiety disorder. 
Psychoneuroendocrinology, 33(10), 1313–1321.  
Verbruggen, F., Aron, A. R., Band, G. P. H., Beste, C., Bissett, P. G., Brockett, A. T., . . . 
Boehler, C. N. (2019). A consensus guide to capturing the ability to inhibit actions 
ANXIETY BIOMARKER 99 
and impulsive behaviors in the stop-signal task. eLife, 8, e46323. 
doi:10.7554/eLife.46323 
Vermani, M., Marcus, M., & Katzman, M. A. (2011). Rates of Detection of Mood and 
Anxiety Disorders in Primary Care: A Descriptive, Cross-Sectional Study. The 
Primary Care Companion to CNS Disorders, 13(2), PCC.10m01013. 
doi:10.4088/PCC.10m01013 
Waghorn, G., Chant, D., White, P., & Whiteford, H. (2005). Disability, employment and 
work performance among people with ICD-10 anxiety disorders. Australian and New 
Zealand Journal of Psychiatry, 39(1–2), 55–66.  
Waghorn, G. R., & Chant, D. C. (2005). Employment restrictions among persons with ICD-
10 anxiety disorders: characteristics from a population survey. Journal of anxiety 
disorders, 19(6), 642–657.  
Watson, D., & Clark, L. A. (1984). Negative affectivity: The disposition to experience 
aversive emotional states. Psychological Bulletin, 96(3), 465–490. doi:10.1037/0033-
2909.96.3.465 
Watson, D., O'Hara, M. W., & Stuart, S. (2008). Hierarchical structures of affect and 
psychopathology and their implications for the classification of emotional disorders. 
Depression and anxiety, 25(4), 282–288.  
Watt, D. F., & Panksepp, J. (2009). Depression: An evolutionarily conserved mechanism to 
terminate separation distress? A review of aminergic, peptidergic, and neural network 
perspectives. Neuropsychoanalysis, 11(1), 7–51.  
Wintink, A. J., Segalowitz, S. J., & Cudmore, L. J. (2001). Task complexity and habituation 
effects on frontal P300 topography. Brain and Cognition, 46(1), 307–311. 
doi:https://doi.org/10.1016/S0278-2626(01)80090-7 
ANXIETY BIOMARKER 100 
Wittchen, H.-U., Kessler, R. C., Beesdo, K., Krause, P., Höfler, M., & Hoyer, J. (2002). 
Generalized anxiety and depression in primary care: prevalence, recognition, and 
management. The Journal of clinical psychiatry.  
Woodnorth, M.-A., & McNaughton, N. (2002). Similar effects of medial supramammillary or 
systemic injection of chlordiazepoxide on both theta frequency and fixed-interval 
respondin. Cognitive, Affective, & Behavioral Neuroscience, 2(1), 76–83. 
doi:10.3758/CABN.2.1.76 
World Health Organization. (2004). ICD-10 : international statistical classification of 
diseases and related health problems : tenth revision (2nd ed ed.). Geneva: World 
Health Organization. 
World Health Organization. (2017). Depression and other common mental disorders: global 
health estimates.  
World Health Organization. (2018). International Classification of Diseases for Mortality 
and Morbidity Statistics Vol. 11th Revision.  Retrieved from 
https://icd.who.int/browse11/l-m/en  
Yamanaka, K., & Yamamoto, Y. (2010). Single-trial EEG power and phase dynamics 
associated with voluntary response inhibition. Journal of Cognitive Neuroscience, 
22(4), 714–727.  
Young, C. K., & McNaughton, N. (2008). Coupling of theta oscillations between anterior and 
posterior midline cortex and with the hippocampus in freely behaving rats. Cerebral 
Cortex, 19(1), 24–40.  
Zhang, S., McIntosh, J., Shadli, S. M., Neo, P. S. H., Huang, Z., & McNaughton, N. (2017). 
Removing eye blink artefacts from EEG—A single-channel physiology-based 
method. Journal of neuroscience methods, 291, 213–220. 
doi:http://dx.doi.org/10.1016/j.jneumeth.2017.08.031 
ANXIETY BIOMARKER 101 
Zhou, Y., Cao, Z., Yang, M., Xi, X., Guo, Y., Fang, M., . . . Du, Y. (2017). Comorbid 
generalized anxiety disorder and its association with quality of life in patients with 























ANXIETY BIOMARKER 102 
Appendix A: Information and Consent Forms 
 
 
Stop Signal EEG and Personality 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 
7634) 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet carefully. 
Take time to consider and, if you wish, talk with relatives or friends, before deciding whether 
or not to participate. If you decide to participate we thank you.  If you decide not to take part 
there will be no disadvantage to you and we thank you for considering our request. 
What is the aim of this research project? 
This project investigates how the electrical activity of your brain varies when you are trying 
to stop a response once you have started making one. We are particularly interested in how 
one specific brain rhythm (which appears when stopping and going are in conflict with each 
other) relates to current questionnaires that measure anxiety-related traits. The results should 
show how the various personality trait measures relate to trait variation in the conflict 
response and should also provide a basis for developing a new conflict response scale, 
extreme responses on which could potentially be used to diagnose a specific kind of anxiety 
disorder. The brain rhythm data will also provide a reference population against which 
clinical groups can be compared in future. 
Who is funding this project?  
This project is part of the work funded by a grant to Professor Neil McNaughton and 
collaborators at the University of Otago and the University of Auckland from the Health 
Research Council of New Zealand. 
Who are we seeking to participate in this project? 
We are seeking participants who are 18-40 years old, healthy (with no major illness in the 
previous 30 days), with no regular use of psychotropic medication in the last 6 months and no 
use of alcohol in the 24 hours before testing. You should be willing to receive medical and 
psychiatric screening interviews and undergo a urine test for psychotropic compounds. 
You will NOT be able to participate in the project because it may involve an unacceptable 
risk to you if have: 
1. Susceptibility to photosensitivity. 
2. A history of seizure. 
3. A history of allergic skin reactions to chemical agents including detergents. 
If you participate, what will you be asked to do? 
For the main part of the test, we will record the electrical activity from your scalp, heart and a 
finger during a ten minute rest period and in a “stop signal” task with stimuli delivered on a 
computer screen and through earphones and to which you will make responses using a 
computer mouse. You will be interviewed about your physical and mental health and also be 
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asked to complete several questionnaires that measure aspects of your mood and personality. 
The whole experiment will take about three hours. In recognition of the time, inconvenience, 
and travel costs in attending for testing, you will be compensated at a rate of $15 for each 
hour of attendance.  
Preparation for the experiment 
Hair products and natural oils on our scalp make it difficult to record your brain activities. It 
is important to us that you come with a clean scalp. Please avoid using any hair products on 
the day of the experiment.  We recommend that you wash your hair on the day or the day 
before and avoid using a hair conditioner. For participants with glasses, we also recommend 
that you wear contact lenses if possible for your own comfort.  
Electrical recording procedure 
You will put on an electro-cap as shown in the picture. We will fill the 
electrodes (small metal discs) attached to the cap with a gel that conducts 
brain signals from your scalp to our recording system. To achieve good 
recordings, we will abrade your skin gently before applying the gel. The 
electrodes are then connected to an amplifier that allows us to record 
your brain rhythms (EEG). We will also attach stick-on electrodes to 
your body to record your heart activity (ECG) and a clip on electrode to 
an index finger to measures your skin resistance/perspiration (GSR). The whole system is 
regularly tested and passes the current standards for connecting electrical equipment to 
people. 
Is there any risk of discomfort or harm from participation? 
There is a risk of allergic skin reaction to the electrode gel and of minor discomfort from the 
abrasion of the skin surface during gel application. Exposure to stimuli on a computer screen 
has a rare risk of inducing seizures in those with or without a history of seizure. If you have a 
history either of photosensitivity or of any form of seizure you should not take part. The 
person running your electrical testing is required to be trained in the procedures for 
connecting you to the equipment and to have a current First Aid Certificate (with training 
renewed every two years by the New Zealand Red Cross) so that they can respond 
appropriately to any unexpected adverse events that occur during testing. 
What data will be collected, and how will they be used? 
Your physical and mental health status, questionnaire scores, and elecgtrical recordings will 
be stored in secure computer databases and will be identified only with your participant 
number. Any paper records will be stored securely in locked filing cabinets. Health status 
will be assessed only to exclude participants who do not meant the entry criteria. 
Questionnaire and electrical data will be subjected to group statistical analysis to determine 
general group-wide personality trait relationships and reference data. Urine samples, 
identified only by participant number, will be disposed of by the analysing laboratory using 
their usual procedures and only the qualitative, present/absent, result returned by the 
laboratory will be used for inclusion/exclusion. Data will be stored for 10 years and then 
deleted. 
What about anonymity and confidentiality? 
No identifying data will be recorded. All collected data will be linked only to your participant 
number. All data will be stored securely and accessed only by study personnel. Reporting of 
the completed research will be of aggregated data over all participants and no data will be 
reported linked to an individual participant number. 
Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time and without any disadvantage 
to yourself of any kind. 
What if Participants have any Questions? 
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If you have any questions about our project, either now or in the future, please feel free to 
contact either:- 
 
Shabah Shadli (Telephone: 03 479 5835) or Professor Neil McNaughton (Telephone: 03 479 
7634) shabah.shadli@otago.ac.nz   nmcn@psy.otago.ac.nz 
 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 
15/005). If you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any 
issues you raise will be treated in confidence and investigated and you will be informed of the outcome. 
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Stop Signal EEG and Personality 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 
7634) 
CONSENT FORM FOR PARTICIPANTS 
1. I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
2. I have had sufficient time to talk with other people of my choice about participating in the 
study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I understand 
that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to withdraw 
from the project at any time without disadvantage. 
6. I am aware that undergraduate students will be present and will carry out some parts of the 
experiment. 
7. I know that as a participant I will undergo electrical (EEG/ECG/GSR) testing, physical and 
mental health screening, and a qualitative urine test for psychotropic drugs and complete 
questionnaires assessing emotion, as listed in the information sheet. I understand that I may 
decline to answer any interview or questionnaire question without disadvantage of any kind. 
8. I know that no personal identifying information will be included in the paper records and 
electronic files which represent the data from the project, and that these will be placed in 
secure storage and kept for at least ten years.  
9. I understand the nature and size of the risks of discomfort or harm that are explained in the 
Information Sheet, including the rare risk of computer screen-induced seizures. 
10. I understand that the results of the project may be published but my anonymity will be 
preserved and only group data reported. 
 




   (Full name) 
 
 
.............................................................................   ............................... 
       (Signature of participant)      (Date) 
 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 
15/005). If you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any 
issues you raise will be treated in confidence and investigated and you will be informed of the outcome. 
 




EEG Testing for an Anxiety Process 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 
7634) 
INFORMATION SHEET FOR PATIENTS 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet carefully. 
Take time to consider and, if you wish, talk with relatives, friends, or your doctor, before 
deciding whether or not to participate. If you decide to participate we thank you.  If you 
decide not to take part there will be no disadvantage to you and we thank you for considering 
our request. 
What is the aim of this research project? 
This project investigates how the electrical activity of your brain varies when you are trying 
to stop a response once you have started making one. We are particularly interested in how 
one specific brain rhythm (which appears when stopping and going are in conflict with each 
other) relates to current questionnaires that measure anxiety-related traits. The results should 
show how the various personality trait measures relate to trait variation in the conflict 
response and should also provide a basis for developing a new conflict response scale, 
extreme responses on which could potentially be used to diagnose a specific kind of anxiety 
disorder. We predict that some people with any of a range of anxiety symptoms will have a 
stronger conflict brain rhythm compared both to other people with much the same anxiety 
symptoms and to a non-clinical population. We expect this stronger rhythm will be linked to 
a greater treatment response. It is important for us that we measure this rhythm before you 
receive any treatment as we already know that a variety of anti-anxiety drugs strongly affect 
it. 
Who is funding this project?  
This project is part of the work funded by a grant to Professor Neil McNaughton and 
collaborators at the University of Otago and the University of Auckland from the Health 
Research Council of New Zealand. 
Who are we seeking to participate in this project? 
We are seeking participants who are 18-40 years old, who are suffering from ongoing 
symptoms of anxiety, fear, or panic and who are intending to seek treatment for this. You 
should otherwise be healthy (with no major illness in the previous 30 days), with no regular 
use of psychotropic medication in the last 6 months and no use of alcohol in the 24 hours 
before testing. You should be willing to receive medical and psychiatric screening interviews; 
be willing for us to contact your GP prior to the commencement of the study, if necessary, 
about your medical history; and be willing to undergo a urine test for psychotropic 
compounds immediately prior to EEG testing. 
 
You will NOT be able to participate in the project, because it may involve an 
unacceptable risk to you, if you have: 
1. Susceptibility to photosensitivity. 
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2. A history of seizure. 
3. A history of allergic skin reactions to chemical agents including 
detergents. 
If you participate, what will you be asked to do? 
For the main part of the test, we will record the electrical activity from 
your scalp, heart and a finger during a ten minute rest period and in a 
“stop signal” task with stimuli delivered on a computer screen and 
through earphones and to which you will make responses using a 
computer mouse. You will be interviewed about your physical and 
mental health and also be asked to complete several questionnaires that 
measure aspects of your mood and personality. The whole experiment 
will take about three hours. You will also be asked to return to the laboratory at 3 months and 
6 months after your initial testing session at which time we will give you a brief interview to 
determine any changes in your anxiety-related symptoms, ask you to report on any treatment 
you have received since the initial testing session, and fill out some of the original 
questionnaires for a second time. These follow up tests are likely to take about one hour. In 
recognition of the time, inconvenience, and travel costs in attending for testing, you will be 
compensated at a rate of $15 for each hour of attendance at the end of each test period. 
Preparation for the experiment 
Hair products and natural oils on our scalp make it difficult to record your brain activities. It 
is important to us that you come with a clean scalp. Please avoid using any hair products on 
the day of the experiment.  We recommend that you wash your hair on the day or the day 
before and avoid using a hair conditioner. For participants with glasses, we also recommend 
that you wear contact lenses if possible for your own comfort.  
Electrical recording procedure 
You will put on an electro-cap as shown in the picture. We will fill the electrodes (small 
metal discs) attached to the cap with a gel that conducts brain signals from your scalp to our 
recording system. To achieve good recordings, we will abrade your skin gently before 
applying the gel. The electrodes are then connected to an amplifier that allows us to record 
your brain rhythms (EEG). We will also attach stick-on electrodes to your body to record 
your heart activity (ECG) and a clip on electrode to an index finger to measures your skin 
resistance/perspiration (GSR). The whole system is regularly tested and passes the current 
standards for connecting electrical equipment to people. 
Is there any risk of discomfort or harm from participation? 
There is a risk of allergic skin reaction to the electrode gel and of minor discomfort from the 
abrasion of the skin surface during gel application. Exposure to stimuli on a computer screen 
has a rare risk of inducing seizures in those with or without a history of seizure. If you have a 
history either of photosensitivity or of any form of seizure you should not take part. The 
person running your electrical testing is required to be trained in the procedures for 
connecting you to the equipment and to have a current First Aid Certificate (with training 
renewed every two years by the New Zealand Red Cross) so that they can respond 
appropriately to any unexpected adverse events that occur during testing. 
 
What data will be collected, and how will they be used? 
Your physical and mental health status, questionnaire scores, and electrical recordings will be 
stored in secure computer databases and will be identified only with your participant number. 
Identifying data, including the identity of your GP, will be stored separately from the study 
data and will be used only for contact purposes. Any paper records will be stored securely in 
locked filing cabinets. Physical health status will be assessed only to exclude participants 
who do not meet the entry criteria. Mental health status will be assessed to allow exclusion of 
ANXIETY BIOMARKER 108 
some conditions but, in particular, will be used to assess the classification of your anxiety 
disorder within the DSM diagnostic system. Your questionnaire, diagnostic and electrical 
data will be subjected to group statistical analysis to determine general group-wide 
personality trait relationships and differences from reference data. Urine samples, identified 
only by participant number, will be disposed of by the analysing laboratory using their usual 
procedures and only the qualitative, present/absent, result returned by the laboratory will be 
used for inclusion/exclusion. Data will be stored for 10 years and then deleted. 
What about anonymity and confidentiality? 
All information generated in this study will be considered highly confidential and must not 
be disclosed to any persons not directly concerned with the study. However, authorized 
regulatory officials and sponsor personnel will be allowed full access to the records. Only 
participant initials and unique participant study numbers will identify participants on data 
documents or in the database and identity data will be stored separately.  However, 
participants’ full names may be made known to a regulatory agency or other authorized 
official (e.g. GP) if necessary. All data will be stored securely and accessed only by study 
personnel. Reporting of the completed research will be of aggregated data over all 
participants and no data will be reported linked to an individual participant number. 
Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time and without any disadvantage to 
yourself of any kind. 
What if Participants have any Questions? 
If you have any questions about our project, either now or in the future, please feel free to 
contact either:- 
Shabah Shadli (Telephone: 03 479 5835) or Professor Neil McNaughton (Telephone: 03 479 
7634) shabah.shadli@otago.ac.nz   nmcn@psy.otago.ac.nz 
 
 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 
15/005). If you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any 
issues you raise will be treated in confidence and investigated and you will be informed of the outcome. 
 
  






Stop Signal EEG and Personality 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 
7634) 
CONSENT FORM FOR PATIENTS 
1. I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
2. I have had sufficient time to talk with other people of my choice about participating in the 
study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I understand 
that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to withdraw 
from the project at any time without disadvantage. 
6. I am aware that undergraduate students will be present and will carry out some parts of the 
experiment. 
7. I know that as a participant I will undergo electrical (EEG/ECG/GSR) testing, physical and 
mental health screening, and a qualitative urine test for psychotropic drugs and complete 
questionnaires assessing emotion, as listed in the information sheet. I understand that I may 
decline to answer any interview or questionnaire question without disadvantage of any kind. 
8. I know that no personal identifying information will be included in the paper records and 
electronic files which represent the data from the project, and that these will be placed in 
secure storage and kept for at least ten years.  
9. I understand the nature and size of the risks of discomfort or harm that are explained in the 
Information Sheet, including the rare risk of computer screen-induced seizures. 
10. I understand that the results of the project may be published but my anonymity will be 
preserved and only group data reported. 
 
I agree to take part in this project.  
I agree that my GP can be contacted for information about my health and to receive health 
related information about me from this project 
 
…………………………………………………                     
…………………………………… 
   (Full name)      (GP name, location) 
 
 
.............................................................................   ............................... 
    
       (Signature of participant)      (Date) 
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This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 
15/005). If you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any 
issues you raise will be treated in confidence and investigated and you will be informed of the outcome. 
